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The hypocretin receptor 1 (HCRTr1) is a critical participant in the regulation of 
motivated behavior and dopamine (DA) signaling, likely through actions on the VTA. 
However, while hypocretin signaling appears to influence some degree of VTA 
activity, its ongoing neuromodulatory role remains somewhat unknown. To further 
examine the involvement of VTA-HCRTr1 in regulating reward and reinforcement 
processing, we develop a viral technique to induce long-term knockdown of HCRTr1 
expression in the VTA, and measure effects on motivated behavior, DA 
neurotransmission, and cell activity in the nucleus accumbens (NAc). We determine 
that viral knockdown induces sustained downregulation of HCRTr1 specifically in VTA, 
without producing toxicity, and without altering the expression of proteins important 
for DA synthesis and transport. HCRTr1 knockdown also delays the acquisition of 
cocaine self-administration, and reduces the motivation to pursue cocaine reinforcers, 
without affecting arousal. Additionally, we observe that HCRTr1 knockdown 
dramatically reduces baseline dopamine release, and attenuates the effects of cocaine 
on DA uptake. We then targeted HCRTr1 in only dopamine-producing cells of the 
xiii 
 
VTA, and determined that such knockdown reduces DA release under low doses of 
cocaine, while impairing the inhibition of DA uptake inhibition of high dose of cocaine, 
and changes the firing pattern of cells in the NAc.  Together this research helps 
establish viral knockdown as an important experimental technique, and provides 









Hypocretins (also known as Orexins), belong to a family of hypothalamic 
neuropeptides. These peptides, named for their initial resemblance to secretin, (a 
peptide secreted during the duodenum during digestion) [1], perform many 
important and specialized roles within the CNS.  The hypocretin system is comprised 
of two neuropeptides (hypocretin 1/HCRT-1 and hypocretin 2/HCRT-2), and two 
hypocretin receptors (hypocretin receptor 1/HCRTr1 and hypocretin receptor 
2/HCRTr2) [2].  
 
 
The hypocretin peptides 
 
Both hypocretin peptides, (also called orexin A and orexin B), are cleaved from the 
same precursor protein (pre-prohypocretin)[3], which is encoded by a gene located at 
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human chromosome 17q21.2 [2]. Both forms of hypocretin peptide are comprised of 
a relatively short-length peptide chain. Although HCRT-1 and HCRT-2 contain 46% 
sequence homology, their associated receptor binding and neurological roles, are 
quite different. As the hypocretin receptors represent the site where hypocretins begin 
to affect cellular physiology, and the site of action for pharmacotherapies that target 
the system, they are the primary focus of this investigation.  
 
 
Hypocretin receptor binding 
 
The hypocretin receptor 2 (HCRTr2) binds to both hypocretin peptides with roughly 
equal affinity, but the HCRTr1 is said to possess an approximately 10 fold greater 
affinity for hypocretin peptide 1 (HCRT-1) [4]. The difference in binding affinity is due 
to many factors, but a particularly important component appears to be the different 
orientations of the amino acids in the two peptides [5] and in the receptors [4]. HCRT-1 
peptide contains a pyroglutamine at its N-terminus, and a tertiary structure, which is 
folded inward towards the C-terminus, which increases its likelihood of binding to the 
HCRTr1. (Figure 1). In addition, HCRT-1 is a slightly larger molecule, comprised of 33 
amino acids, (compared with 28 for HCRT-2), a feature which gives it a high specificity 
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for the long, straightened binding site of HCRTr1 [4]. By comparison, the HCRT-2 
peptide contains a more obliquely folded tertiary configuration (Figure 1) [4]. This 
configuration leads to greater affinity for the HCRTr2, since this receptor contains a 
slightly more open alignment than HCRTr1, a feature that enables greater binding to 
the conserved 26-AA sequence in both peptides. The more open configuration of 
HCRTr2 allows greater accommodation of both the “kinked” region of HCRT-2 and the 
more stretched out tertiary structure of HCRT-1 [5].   These differences lead to 
different binding affinities at the two hypocretin receptors, and may ultimately provide 
a basis for the differing roles of the two receptors within the CNS.  
 
Hypocretin receptor pharmacology 
 
While hypocretin receptors bind to their respective ligands with different affinities, and 
contain different surface orientations, much of the internal structure and function of 
HCRTr’s is somewhat consistent between the two receptor types. Both HCRTr1 and 
HCRTr2 are 7-transmembrane receptors; their tertiary structures cross the lipid bilayer 
of the cell membrane 7 times, and are anchored by proteins such as CD200 [6]. 
Immediately, ligand binding to either receptor causes the opening of monoprotic 
cation channels [7, 8] and calcium channels of the L-type [9] [9] and T-type variety 
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[10], leading to immediate increases in cellular excitability. Binding to either receptor 
also appears to suppress potassium conductance [11-13], further promoting 
depolarization. As both HCRTr1 and HCRTr2 are metabotropic g protein-coupled 
receptors [14, 15], ligand binding on both receptors also induces longer term 
excitability by changing the configuration of the attached chain of linked G protein 
subunits, generally separating the alpha subunit from the beta and gamma subunits 
to trigger the signaling pathway. Consequently, ligand binding to hypocretin receptors 
induces a series of downstream effects on cellular function, in addition to immediate 
changes in cation permeability. The metabotropic signaling pathway of HCRTr1 is 
largely considered to be G (q alpha), though other [4] isoforms also exist  [14]. This 
means that stimulation of the receptor causes G-protein driven activation of 
phospholipase C, which then cleaves the membrane phospholipid PiP2 into two parts. 
One part becomes inositol tri-phosphate, which acts on the intracellular IP3 receptors 
to release intracellular calcium, and further increase cellular excitability. The other 
cleaved half of PiP2 becomes diactylglycerol, which stimulates many cellular pathways, 
beginning with protein kinase C/PKC [16]. Protein Kinase C then catalyzes the 
activation of many other enzymes, and increases cellular metabolic processes. This 
relationship is considered critical, as many studies have correlated HCRT receptor 
binding with increased calcium signaling and PKC activity [17]. However, there are 










Figure 1. Hypocretin Receptors and Associative binding. The hypocretin system is 
comprised of two receptors and two peptides. Hypocretin peptide 1 has a near equal 
affinity for hypocretin receptors 1 and 2, while hypocretin peptide 2 preferentially 




Notably, HCRTr1 appears to utilize predominantly Gq and Gas-driven signaling, while 
HCRTr2 contains Gq, Gs, and Gi signaling [18]. This is an important distinction, as Gs 
and Gi are powerful regulators of adenylate cyclase, and can strongly influence the 
degree of cAMP production in the cell [18]. As in this case, many important 
downstream effectors can be regulated bidirectionally through HCRTr2. This makes 
sense, as many cAMP-driven kinases have been linked to HCRTr2 activity, including 
protein kinase A/PKA [19], and extracellular-regulated kinase/ERK[20]. These effects 
compound HCRTr2’s already significant influence on PKC [21], and go a long way 
towards driving the state of activity in cells. All of these downstream effectors can alter 
cellular functioning in a myriad of ways, and the ultimate role of HCRT in regulating 
cell activity is still being uncovered. Given that HCRTr1 and HCRTr2 follow different 
patterns of distribution in the brain, understanding the differences in downstream 
signaling, combined with differences in receptor expression (detailed below) may be 
critical for discerning how hypocretin signaling affects cellular activity over the short 
and long term, and will provide invaluable insights into how the system influences 
behavior.  
 
As a result of both the direct and downstream effects of ligand binding, HCRTr1 is 
considered to be strongly influential on cellular excitability [22]). Infusions of HCRT-1 
peptide can lower the threshold of excitation in dopaminergic [23] and glutamatergic 
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[24, 25] neurons of the VTA.  In addition, administration of the HCRTr1 antagonist SB-
334867, (which preferentially reduces binding of HCRT-1 to HCRTr1 via allosteric 
blocking), can blunt the effects of psychostimulants on DA cell firing [26]. Further,  SB-
334867 can even attenuate the increase in DA cell firing which arises from stimulation 
of other brain regions, such as the mPFC [27].  Such effects appear to be 
longstanding, as increased stimulation of HCRTr1 for even several minutes can result 
in excitability and neurochemical changes which can persist for well over an hour [23]. 
 
Patterns of hypocretin receptor distribution 
 
Both hypocretin peptides are produced in the lateral hypothalamus and perifornical 
area, with small pockets of HCRT producing cells in other places [2, 7]. HCRT-1 and 
HCRT-2 are sometimes released together by the same cells, occasionally alongside 
dynorphin (another peptide which may act as a counterweight to some of the effects 
of HCRT) [23, 28]. However, while HCRT-1 and HCRT-2 are produced in the same 
regions, there are substantial differences in the distribution pattern of the two 
hypocretin receptors [29, 30], which affects their cellular impacts. The differences in 
receptor distribution patterns may help explain why HCRT-1 and HCRT-2 may have 
different behavioral impacts upon the brain. When appearing as the only hypocretin 
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receptor, HCRTr2 appears to be largely concentrated within several hypothalamic 
regions, layer 6 of the cortex, and the hippocampus. By comparison, HCRTr1 appears 
to be concentrated on sites of monoamine production, such as the Locus Coeruleus, 
the Bed Nucleus of the Stria Terminalis, the Dorsal Raphe, and the Ventral Tegmental 
Area [30], TABLE 1. Such patterns are consistent with the observed physiological 
impacts of HCRTr signaling; HCRTr2 is considered crucial for controlling feeding 
behaviors and hyperactivity [31]. By comparison, the roles of memory consolidation, 
associative learning, and arousal all involve the activity of HCRTr1, (along with 
significant participation from HCRTr2). That many behaviors do involve both receptors 
is unsurprising from a pharmacological standpoint, as HCRT-1 is capable of 
stimulating both hypocretin receptors [32]. Nevertheless, most of the sites considered 
important for motivated behavior and conditioning appear to involve HCRTr1 
signaling, sometimes in the absence of HCRTr2 [33]. As such, HCRTr1 may ultimately 
be the stronger effector of behavioral motivation, and reward processing.  
 
Influences on hypocretin activity 
 
The activity of the HCRT system is subject to a high degree of regulation. Many 
environmental factors can lead to significant changes in the expression of both 
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hypocretin receptors, and in tissue concentrations of hypocretin peptides. For 
instance, early life stress can profoundly reduce the expression of both HCRTr1 and 
HCRTr2 across the brain [34] in adult mice, and substantially reduce HCRT-1 peptide 
levels in CSF. HCRT signaling can also be modulated by other forms of early influence, 
including drugs of abuse. Prenatal nicotine exposure increases both the number of 
HCRT-producing neurons [35], and the number of hypocretin receptors [36], an effect 
which is also observed with ethanol [37]. These types of effects are not specific to 
motivation. Sustained HCRTr1 expression appears to be altered in a gender-specific 
fashion in patients with depression [38], and treatments which target the HCRT system 
have indeed shown promise at treating depression [39] and narcolepsy [40]. Such 
effects are typically present from an early age, strongly implicating the HCRT system in 
many forms of behavior.  
 
These effects appear particularly relevant to the field of addiction. Many drugs of 
abuse appear to increase the activity of HCRT neurons, including cocaine [33] and 
alcohol [27]. As discussed in detail later in this document, such findings denote the 





Behavioral relevance of hypocretins 
 
According to a large body of research, the excitatory effects that hypocretins exert on 
cells can confer many significant impacts on behavior. When the system was first 
discovered in the late 1990s, two primary behavioral roles were ascribed to the 
system, by the two research teams that discovered hypocretins nearly simultaneously. 
The first group, led by Luis de Lecea and JW Sutcliffe, categorized these new 
molecules as hypocretins. This group determined that hypocretins bind to unique 
receptors in many regions of the brain, and increase the neurons’ state of excitability 
[2]. The neuropeptides were named “hypocretins” on account of being hypothalamic 
molecules that bear a resemblance to secretin.  The first research group to 
characterize the hypocretin molecules, working in the laboratory of Dr. J. Robert 
Sutcliffe , would go on to demonstrate how hypocretin receptors contribute 
significantly to physiological functioning.  In particular, there have been many 
important discoveries, which highlight the connections between hypocretin and 
arousal. First, disruptions to the function or structure of HCRT’s or HCRTr’s can result 
in sleep disorders such as narcolepsy [3]. Notably, a line of dogs currently used as a 
model to study narcolepsy contain a mutation to the HCRTr2 [41]. The HCRT system is 
critical for mediating transitions to awake states [42], and deficits to HCRT activity can 
lead to a correspondingly significant disruption in normal sleep/wake transitions [43, 
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44]. Indeed, HCRT peptides have been shown to induce waking through a variety of 
mechanisms, such as increasing the excitation of the pontine reticular formation [45], 
inhibiting the ventrolateral preoptic area [46], and stimulating the locus coeruleus [42]. 
Since diminished levels of HCRT peptides are also observed in people with sleep 
disorders like narcolepsy [3], it is unsurprising that many components of the arousal 
system are often disturbed by HCRT dysfunction. This makes sense, considering the 
relative distribution pattern of hypocretin receptors. These receptors, particularly 
HCRTr1, are found extensively on brain centers that promote arousal, including the 
locus coeruleus [47].  As a result, HCRTs are of major importance to sleep research; 
many sleep aids have strong actions on HCRTrs, including Modafinil [48]. Many of the 
proposed treatments for insomnia or narcolepsy (or “non-24”) which target the HCRT 
system often affect activity at both HCRTrs, and are known as Dual Orexin Receptor 
Antagonists [40]. This highlights just a few of the pronounced effects on arousal that 
have been linked to the hypocretin system.   
 
The second group to discover HCRT, working in the laboratory of Dr. Taheshi 
Yanagisawa focused more strongly on the significant correlation between ligand 
binding and feeding behaviors. Accordingly, this research group referred to the class 
of neuropeptides as Orexins, after the Greek root “orexis” (meaning appetite) [49]. The 
Sakurai group, and many other research teams, would go on to establish many 
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connections between the HCRT system and different elements of feeding and satiety. 
In subsequent years, research has linked HCRTr binding to fat cell metabolism [50], 
communication of hunger signals [51], and the consumption and seeking of palatable 
food [52].  Additionally, HCRTs can affect digestive motility [53], food preference [54], 
and can even mitigate the digestive element of the fight-flight response, likely 
through actions on the adrenal medulla [55]. Critically, these effects appear to be 
bidirectional; exciting the HCRT system can have augmenting effects on food 
consumption [52], while HCRT receptor antagonism, particularly antagonism of 
HCRTr1, is widely considered to produce anorexic effects [56]. Indeed, blockade of 
HCRTr binding has been strongly considered as a treatment for obesity [57]. 
 
Hypocretins and reward 
 
While the HCRT system has been shown to possess a considerable degree of 
influence over arousal and metabolic cellular processes, as well as a moderate effect 
on feeding, the most striking function of the system may be its ability to regulate 
reward processing and reward-seeking behaviors. For almost 15 years, research 
studies have linked the HCRT system (and particularly HCRTr1) to behavioral 
motivation and addictive processes. For example, infusions of HCRT-1 peptide 
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increase self-administration of cocaine [58], increase alcohol consumption [59], and 
reinstate food-based responding [60]. In addition to boosting reward seeking and 
consummatory behavior for many reinforcers, HCRTs can also alter the process of 
sensitization to drugs of abuse [61], particularly cocaine [62]. Infusion of HCRTs can 
also increase the amount of time spent in reward-paired environments [63], and alter 
the threshold of intracranial self-stimulation [64]. Such effects are largely reciprocal; as 
prolonged bouts of highly motivated behaviors, particularly behaviors associated with 
the seeking or taking of drugs of abuse, also tend to increase the fos activity of cells 
which produce HCRTs [27]. For instance, prolonged cocaine use increases HCRT 
peptide concentration in the lateral hypothalamus [65] and increases the activity of 
neurons in the perifornical region of the hypothalamus [66]. The exact nature of this 
bidirectional relationship remains somewhat ambiguous; it is not entirely clear whether 
reward-associated behaviors and drugs of abuse trigger an increase in HCRT 
signaling; or whether HCRT signaling promotes reward-seeking behavior. While both 
mechanisms are plausible, there appears to be a strong link between HCRT signaling 






HCRTr1 is critical for the regulation of addictive behaviors 
Although both HCRTrs (and HCRTs) can influence motivated behavior [67], the 
majority of the research appears to suggest that HCRTr1 may drive more of the 
HCRT-mediated actions on behavior. For instance, HCRTr1 blockade was effective at 
reducing cocaine self-administration behavior [67-69], while HCRTr2 blockade was not 
[69]. In addition, HCRT-1 is shown to exert a strong, augmenting effect on cocaine 
seeking [70], and on the preference for a drug-paired environment [71]. In addition, 
there is evidence that reducing HCRTr1 activity can reduce many other forms of 
motivated behavior. For instance, HCRTr1 blockade can reduce conditioned place 
preference (CPP) [72], self-administration [73], and drug-and stress-primed [70] 
reinstatement for cocaine rewards. These effects are not confined to cocaine; 
manipulations to hypocretin signaling can also alter the preference for alcohol [74], 
morphine [75], and even high-fat food [56]. Finally, an important review paper 
produced by the de Lecea research group demonstrated that HCRTr1 is important for 
mediating arousal, feeding, and reward processing [76], suggesting a strong level of 
interplay between HCRTr1-driven effects on arousal and on other behaviors.  The 
robust effects of HCRTr1 on motivated behavior appear to be largely bidirectional. 
Just as HCRTr1 antagonism can reduce several metrics of cocaine-motivated 
behaviors, HCRT-1 can increase motivation for cocaine reinforcement [67, 77], and 
increase responding under discrete trials schedules of reinforcement [77], Such 
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bidirectional effects have been observed with cocaine [78], alcohol [79], and 
amphetamine [63]. Critically, behavioral measures that are unaffected by HCRT-1 
peptides are also largely insensitive to the effects of HCRTr1 antagonism, such as low-
effort responding for reinforcers [80]. Finally, HCRTr1 may play a more dominant role 
in regulating motivated behaviors, compared with HCRTr2. While HCRT-1, (which 
binds to both HCRTr1 and HCRTr2), induces substantial alterations to both cellular 
firing and behavior [81], agents which induce blockade of HCRTr2 do not appear to 
alter motivated behavior to the same extent that HCRTr1 antagonism does [69]. Such 
evidence points to the importance of HCRTr1 as a primary locus of hypocretin 
regulation of motivated behavior. While there is strong evidence to suggest that 
HCRTr2 may be effective at managing arousal levels [82], it appears as though 
HCRTr1 may play the more prominent role in shaping behavioral motivation.  
 
Interest within the pharmaceutical industry 
 
These connections between the HCRTr1 and motivated behavior have been noted 
almost since the discovery of the HCRT system in the late 1990s. Within several years 
of the first published findings, several papers pointed to the effects of hypocretins on 
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reward, and food consumption, and the research has increased significantly ever 
since. These developments have not escaped the notice of the private sector.  
Since the early 2000’s, there have been an increasing number of studies sponsored by 
the pharmaceutical industry, which assess the viability of HCRTrs as therapeutic targets 
for many psychological and physiological conditions. This effort has been 
spearheaded by large companies including Merck and Glaxosmithkline [40], and 
covers a wide range of conditions. Initially, the majority of this work has been 
preclinical, with HCRTr-targeting compounds being evaluated in mostly rodent 
models for the treatment of metabolic-related obesity [83], major depression [84], 
and insomnia [85]. Critically, there has been also been a recent uptick in the number 
of pharmaceutical-sponsored preclinical research studies, which focus on the 
connection to substance abuse. For instance, one study sponsored by J&J and Bristol 
Myers Squibb found that HCRTr2 activity is required for multiple elements of alcohol 
addiction, including place preference, self-administration, and drug-primed 
reinstatement [86]. Additionally, Merck has sponsored research which links cocaine 
seeking to HCRTr1 activity [87], and GSK has sponsored similar studies evaluating 
morphine place preference [88].  
 
In recent years, there have also been an increasing number of clinical studies that 
focus on compounds that selectively target different elements of the HCRT system. 
18 
 
One notable compound, Suvorexant, has passed stage IV [89] of testing and is now 
FDA-approved, (under the brand name Belsomra) for the treatment of insomnia, and 
dozens more have reached stage III of clinical trials [40]. While much of this data 
remains a proprietary secret, there is clearly a growing interest in the HCRT system 
from both the public and private sector. Such research is likely to continue, as many 
compounds, which target the HCRT system, appear to offer a variety of potential 
clinical uses. 
 
Hypocretins and dopamine: overview 
 
Taken together, the strong, bidirectional effects of HCRTr1 manipulations on 
motivated behavior (combined with the specificity of HCRTr1 expression in certain 
brain regions), suggest a potentially powerful link between HCRTs and the 
dopaminergic reward system of the brain. Indeed, there appears to be a significant 
degree of influence of HCRT signaling on dopamine producing areas including the 
VTA. In particular, HCRTr1 appears to drive much of these effects in the VTA, where 
receptor expression is moderately high [30]. Given the ability of HCRT-1 to increase 
excitability and cellular metabolism, combined with the high density of HCRTr1 (but 
relatively lower HCRTr2) expression in certain areas of the brain, (TABLE 1), which are 
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considered crucial for driving both motivated behavior and dopamine signaling, it is 
likely that HCRTr1 may be driving much of the HCRT influence on reward processing 
through changes to dopamine (DA) signaling.  
 
The dopaminergic system 
 
The mesolimbic dopamine system is a critical circuit for modulating motivated 
behavior, and is widely considered to be one of the regions of the brain which is most 
altered during drug addiction [90]. The system is widely conserved across many 
mammalian species [91]. In large part, this high level of conservation exists within the 
system because it is critical for many forms of learning, including cue-reinforcer 
pairing and associative conditioning [92], reward-seeking [93] and aversive avoidance 
[94]. Lesions or disruptions to areas which produce dopamine often carry significant 
behavioral effects [95], while manipulations that augment the activity of the region 
can often promote reward-seeking and other forms of behavior [96], including 
lowering the threshold of intracranial self-stimulation [97]. Indeed, intracranial self-
stimulation of the VTA or medial forebrain bundle, (which relays information from the 
VTA to efferent regions in the forebrain), is considered one of the most strongly 
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reinforcing sensations possible; animals will self-administer such electrical stimulations 
to the exclusion of all else, including food, water, and sex [98].  
 
While there are important differences in how the mesolimbic system is organized, 
across the different orders of mammalian species, the basic structure of the system is 
largely conserved, from murine rodents (rats and mice) all the way through primates 
and humans [91]. Briefly, the mesocorticolimbic system is comprised of many large 
neurons, which synthesize dopamine, and originate in the ventral region of the 
brainstem (the system also contains inhibitory GABAergic interneurons and a number 
of supportive glia). Although the specific location of these projection neurons may 
vary slightly across species, in most animals they are concentrated in the ventral, 
medial aspects of the tegmentum, directly lateral to the dopaminergic elements of the 
motor system [99]. These neurons are defined by their large size (typically greater 
than 25um) [100], a multipolar orientation, and by their specific electrophysiological 
properties. For instance, dopaminergic cells have a resting membrane potential near -
68mV, and a typical firing rate of 0.5-2Hz. [81].  
 
When a sufficient level of stimulation occurs in the VTA, certain projection cells release 
dopamine, though some also corelease glutamate [101] to downstream projection 
21 
 
targets in the prefrontal cortex, bed nucleus of the stria terminalis, and nucleus 
accumbens/NAc (in the ventral striatum) [102]. Nearby, dopamine neurons in the 
substantia nigra pars compacta also send projections to the cortex and to the 
caudate-putamen, but this pathway is considered to be more relevant to motor 
activity, as opposed to motivated behavior [103]. The projection from the ventral 
tegmental area to the nucleus accumbens is considered the most significant 
connection in the mesolimbic pathway [102], and carries many behavioral 
implications. DA signaling into the NAc is critical for supporting the motivation for 
both cocaine [104] and natural [105] rewards.  
 
Dopamine release often occurs via two patterns. The underlying, non-event driven 
baseline release is referred to as the tonic form of release. It is comprised by a 
relatively constant level of low-volume release of dopamine into the NAc, prefrontal 
cortex, and other regions [106]. This is said to describe the baseline level of activity in 
the mesolimbic dopaminergic system. Tonic release is considered a strong indicator of 
the overall level of excitability of the mesocorticolimbic dopamine system [107], and 
may be a contributing factor in the likelihood of developing substance abuse 
problems [108]. As such, manipulations that alter the excitability of dopaminergic cells 
(and therefore the tonic release pattern), also appear to modulate motivated 
behaviors [109], and may be of critical importance in modulating addictive behaviors.  
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The other form of dopaminergic signaling is known as phasic release. This refers to 
dopamine released during phasic, or burst firing, of dopamine-producing cells [110]. 
Phasic firing can induce an acutely high level of dopamine release into efferent 
regions, particularly the NAc. Phasic release from the VTA is often relatively intense; 
during periods of strong stimulation to the VTA, local dopamine concentrations can 
reach levels 0.5-1uM, although electrical excitation can increase this figure significantly 
[111]. Phasic dopamine release, briefly, is the concentrated, high-volume dopamine 
release that occurs during periods of strong sustained excitatory input to the ventral 
tegmental area. It is thought to signal the temporal importance of an acute event 
[110]. As such, it is a crucial element in learning and memory, as behavioral or 
environmental events which induce a significant degree of phasic dopamine release 
are generally considered reinforcing, in that such events can promote similar 
behaviors or pursuit of similar cues, in future scenarios [112]. Phasic dopamine release 
is therefore (unsurprisingly), considered a critical element in the addictive process. 
Many substances of abuse, namely cocaine, amphetamine, alcohol, heroin, and others 
[113], can alter the extent of phasic dopamine release. Phasic dopamine levels can be 
modulated by blocking the reuptake of dopamine (a hallmark of cocaine effects), or 
by blocking reuptake and increasing release (amphetamine), by reducing inhibitory 
signals (alcohol and opioids), or through a combination of such measures (designer 
drugs). Phasic release is also strongly regulated by the overall excitability of the 
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dopaminergic cells responsible for producing it, as a higher level of excitation sent to 
dopaminergic cells often triggers a higher degree of phasic release [114].  
 
Regulation of dopamine release and uptake 
 
While cellular excitability is strongly influential in regulating both phasic and tonic 
dopamine release, one of the biggest regulators of overall dopaminergic 
neurotransmission is the rate at which dopamine is recycled through the synapse. 
While dopamine production generally occurs somewhat slowly [115], dopamine can 
be removed from the synapse and prepared for re-release within the order of 
seconds [116]. In the mesolimbic system, the enzyme responsible for the trafficking of 
dopamine out of the synapse is the dopamine transporter (DAT). DAT is a protein that 
is active upon the cell membrane and functions as a symporter, by transporting 
dopamine and sodium into the neuronal cytoplasm. DAT exists only in cells that 
produce dopamine (although it is capable of transporting other monoamines such as 
norepinephrine and serotonin); hence the transporter is entirely presynaptic. The 
relative affinity between dopamine molecules and the DAT is altered by the presence 
of drugs of abuse, such as cocaine and amphetamine. Cocaine exerts its primary 
effects upon the brain by forming a complex with the DAT, rendering it unable to bind 
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with dopamine. This slows the overall rate of dopamine uptake, and increases the 
concentration of dopamine in the DA synapse [117]. For this reason, cocaine, (and 
many other substances which interfere with DAT function) can be extremely addictive 
[117]. The degree to which substances like cocaine can affect the DAT is highly 
dependent on the concentration of the drug at the synapse. Low doses of cocaine 
produce a moderate level of uptake inhibition, and are not considered reinforcing 
until the concentration of the drug reaches a critical level [118]. Additionally, there is a 
ceiling effect of cocaine, beyond which higher doses do not promote further 
responding for the drug [119]. 
 
The ability of cocaine to alter DAT (and to produce reinforcing effects) is dependent 
on the properties of the DAT itself. The impact of stimulants on the DAT is dependent 
on many variables, all of which are related to its ability to bind and move dopamine 
[120, 121].  
 
One key factor affecting the function of DAT is how it is expressed on the surface of 
the cell membrane. Higher cell surface expression of DAT has been shown to strongly 
correlate with greater rate of dopamine uptake [122]. This, in itself, is not surprising, 
dopamine is impermeable to cell membranes, and can only reenter cells via 
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monoamine transporters such as DAT [123]. This is critical for addictive processes 
(which are largely dependent on changes to synaptic dopamine concentrations) [124]. 
DAT surface expression is correlated with higher drug-motivated responding [122], 
and strongly impacts the potency of psychostimulants [125].  
 
Several factors can strongly influence the surface localization (and by extension, 
accessibility to dopamine) of the DAT. One factor is the relative dimerization [126] at 
the cell surface. Dimerization is critical, since transporters that dimerize can work more 
effectively as symporters, and are more likely to maintain the same outward 
configuration [127].  
Another critical factor is phosphorylation [128] of the DAT. Phosphorylation of DAT 
can occur through several different mechanisms, including via PKC and ERK [129], and 
this can strongly affect the configuration and function of the transporter. Finally, 
cellular activity can confer a strong degree of influence on the surface density and 
orientation of the DAT [127]. Taken together, many factors that influence DAT 
function exert a major effect on addictive processes, [130]. 
 
The nucleus accumbens 
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One of the most important areas of DAT function in the mesolimbic system is the 
NAc, an olive-shaped region in the basal forebrain with extensive dopamine recepto 
density. Due to its high density of dopamine receptors, the NAc represents a critical 
region of the brain for processing rewarding stimuli. The region is critical for 
transcribing dopaminergic signals from the VTA, and encoding their initial “hedonic” 
value [131], through connections with other limbic regions [132]. Further, neurons in 
the NAc project to many regions of the brain, where operant conditioning and 
incentive learning are processed in parallel. One region that receives substantial input 
from the NAc is the ventral pallidum, an area of the brain that is critical for 
determining the “pleasure” component of stimuli [133]. This is because the VP is 
responsible for combining and processing signals from the NAc with similarly strong 
inputs from the thalamus and other limbic regions such as the amygdala and 
hippocampus [134]. In addition to sending a major projection to the ventral pallidum, 
the shell of the NAc also sends strong projections to the lateral hypothalamus (which 
produces HCRT peptides), the hippocampus, and the prefrontal cortex, (where its 
signals combine with dopaminergic input from other cells which originate in the 
ventral tegmental area) [135]. While the NAc contains many other projections, such as 
to the thalamus and the cerebellum, it is widely believed that its most important role is 




Medium spiny neurons 
 
One major physiological function of the NAc is to process dopamine signals 
originating from the VTA. The NAc receives a high percentage of DA fibers from VTA 
projection neurons, and has some of the highest densities of dopamine receptors in 
the brain [137]. Compared with the rest of the brain, the NAc is a largely 
homogeneous region, where 95% of the neurons present are medium spiny neurons 
(MSNs); GABAergic cells which contain D1, D2, or both forms of dopamine receptor 
[138]. The relative density of these receptors on the neuron determines the respective 
response to dopamine; D1+ MSNs are more strongly excited by dopamine; while D2+ 
MSNs are largely inhibited by dopamine binding [139].   
 
The effects of dopamine binding on D1+ and D2+ MSNs are largely due to 
differences in the type of g protein coupling; on D1R dopamine binding initiates the 
Gs type signaling cascade, which ultimately stimulates cAMP production and increases 
PKA activity [140, 141]. By contrast, D2+ MSNs, which constitute the bulk of the 
neuronal cell population in the NAc [142], are inhibited by dopamine binding [143]. 
Inhibition occurs in these cells via two means. Immediately, dopamine binding to D2 
causes a conformational change which activates the coupled Gi protein, and causes 
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inhibition of adenylate cyclase, thereby halting cAMP production, and downregulating 
the activity of PKA [144]. Further, D2 ligand binding also triggers beta-arrestin 
signaling to impede Akt and GSK-3 signaling [145], thereby reducing cellular activity in 
the longer term [146]. In cells with both D1 and D2 receptors, some of these opposite 
receptors form a complex on the cell surface, where both are conjoined to a Gq/g11 
set of g-proteins, and the relative activity of adenylate cycles is modulated by the 
excitatory D1 activity and the inhibitory D2 activity [147].  Both D1 and D2 MSNs are 
highly sensitive to changes in dopamine levels, though D2R shows a consistently 
higher affinity for dopamine [148]. Previous studies have shown that even minor 
changes in dopamine levels in striatal dopamine levels can dramatically alter 
excitability of MSNs [149], as well as sensitivity of drugs of abuse [150]. This is a critical 
component of addiction, as all drugs abused by humans appear to increase 
dopamine levels in the NAc [151].  
 
Owing to the high density of dopamine receptors (and the range of downstream 
signaling pathways which they regulate), the NAc region is extremely sensitive to 
alterations that occur in the dopaminergic VTA. For instance, lesions of VTA cause a 
strong decrease in dendritic branching in MSNs [152]. Further, substances that 
increase the activity of dopaminergic cells also induce strong effects on the excitability 
and firing rate of medium spiny neurons in the NAc. This is observed with cocaine 
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[153-155], with alcohol [156], and with opiates [157]. The MSNs exhibit very different 
responses to cocaine, depending on the dopamine receptor they possess. Repeated 
administration of cocaine increases spine density and the frequency of miniature 
excitatory postsynaptic currents, while reducing membrane excitability, in D1+ MSNs, 
while decreasing mEPSPs but having no effect on membrane excitability in D2+ MSNs 
[158]. 
 
Hypocretin regulation of the mesolimbic system: Overview 
 
HCRTr1 appears to exert a strong influence on mesolimbic dopamine signaling. First, 
the receptor has been linked to cellular mechanisms that regulate both the tonic and 
the phasic component of dopaminergic neurotransmission. As previously mentioned, 
the receptor is located extensively on the soma and dendrites of dopamine producing 
cells of the VTA [159]. HCRTr1 mRNA is also found in high density in this region [160], 
where a high percentage of neurons produce dopamine. HCRTr1 can profoundly 
affect both short-term and long-term excitability of cells in the VTA [161], thereby 
modulating both phasic and tonic release, and by extension, motivated behavior.  
 




HCRTr1 appears to exert a substantial effect on dopamine neurotransmission, both 
phasic and tonic. Administration of SB-334867 appears to both reduce dopamine 
release and impair dopamine uptake, as well as blunting the effects of cocaine on 
both measures [67, 69, 77]. This is a critical indicator that multiple components of 
dopamine signaling may be affected by HCRTr1. Crucially, these effects are observed 
whether HCRTr1 antagonists are delivered systemically, or locally into the VTA [80]. 
Alterations to HCRT signaling can also profoundly affect the dopamine response to 
drugs of abuse. For instance, the increase in synaptic DA, which is observed under the 
influence of cocaine, appears to be attenuated by SB-334867 [69, 80, 162]. Similar 
effects are observed with morphine [163], sucrose [164], and amphetamine [165]. 
Taken together HCRTr1 carries significant influence in regulating the dopamine 
response to drugs of abuse. 
 
The effects of HCRTr1 on dopamine are unsurprising, given the high level of HCRTr1 
expression on the dendrites and soma of cells in the VTA [166]. Again, such effects 
appear reciprocal between the DA and HCRT system. First, augmentation of HCRT 
signaling is observed following periods of cocaine abuse [167]. Further, long term use 
of cocaine increases HCRTr1 mRNA levels [167], and increases cFOS activity in the 
lateral hypothalamus and perifornical area, among other places [33]. Hence, it is likely 
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that HCRT-driven actions on behavior and HCRT-driven actions on dopamine may be 
related, and likely involve a significant level of contribution from the VTA.  
 
Similar to its effects on motivated behavior, HCRTr1 manipulations appear to exert a 
bidirectional influence on dopamine signaling, with diminished HCRTr1 activity 
generally corresponding to reduced movement of dopamine into and out of the 
synapse [162]. For instance, we have previously shown the HCRTr1 antagonism 
reduces the cocaine-induced spike in dopamine release, and blunts cocaine’s effects 
on dopamine reuptake [67, 69, 162]. We have also shown that this is largely specific to 
HCRTr1, without a substantial contribution from HCRTr2 [69].  By comparison, 
infusions of HCRT-1 peptide directly into the VTA increase cocaine-induced spikes in 
dopamine release over an extended period of time [77], and also extend the 
amplitude of cocaine-induced inhibition of dopamine uptake [77]. These effects 
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+++ ++ ++ + 
NAc Shell X X X X 
NAc Core X X X X 
VP ++ ++ ++ + 
Basolateral 
Amygdala 










Table 1. Anatomical distribution of HCRTr1 in selected regions of the mesolimbic 
system. Date taken from multiple papers [30, 159, 168, 169]. Column A (HCRTr1 IR 
immunolabelling) refers to relative immunofluorescence observed in coronal brain 
sections, while using a primary antibody for HCRTr1, and a fluorescent-tagged 
secondary antibody. Column B (HCRTr1 mRNA) expression was determined by using 
in-situ hybridization within coronal section, using fluorescently tagged RNA 
complementing the HCRTr1 sequence. Columns C and D (GFP labeling in soma and 
dendrites) were taken from coronal sections of the brains of transgenic mice which 
coexpress GFP with HCRTr1; hence GFP expression is a metric of relative HCRTr1 
expression. Scale for GFP and HCRTr1 IR: X: less than 5 cells/section; + = 5-30 cells 
per section; ++ = 30-200 cells/section; +++ = 200+ cells/section. Scale for HCRTr1 
mRNA levels: X: density indistinguishable from background intensity;  + = low density 
of expression; ++ = moderate density; +++ = highest density. Abbreviations: GFP = 
green fluorescent protein; IR = immunoreactivity; Mrna = messenger RNA; NAc = 
nucleus Accumbens; VP = ventral pallidum.  
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Potential effects of HCRTr1 on cellular physiology  
 
The substantial effects of HCRTr1 activity on cellular excitability can lead to significant 
alterations to the expression of many proteins in affected cells. First, in dopaminergic 
cells of the VTA, changes to cellular activity often involve changes to the expression of 
metabolic proteins such as fos [170] and CREB [171], both of which are subject to 
HCRTr1 regulation. Further, the expression of dopamine-related proteins all possess 
strong ties to hypocretin signaling. TH, DAT, and VMAT all undergo a degree of 
regulation via protein kinase C, which is itself regulated in part through hypocretin 
signaling [17]. Consequently, it is possible that HCRTr1 may affect dopamine release 
and uptake through direct actions on dopaminergic proteins.  An alternative 
explanation is that HCRTr1 may be affecting cellular excitability. For instance, HCRTr1 
antagonists reduce the firing rate of putative dopamine cells arising from the region 
[40]. As dopamine cell firing is strongly correlated with DA release [172], this is a 
significant physiological impact.  Taken together, the manner in which HCRTr1 affects 
dopaminergic signaling represents an important gap in the current research.  
 
Putative effects on medium spiny neurons 
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Whatever the precise mechanisms are through which HCRTr1 influences DA 
neurotransmission, such effects are likely to alter the functioning of downstream 
regions dependent on the VTA for DA input, such as the NAc. As discussed above, 
the NAc forms a large part of the ventral striatum, a region with a very high 
concentration of dopamine receptors [173]. Due to the density of receptors, the NAc 
is also highly sensitive to manipulations which can alter DA signaling. For instance, 
cues which predict cocaine reinforcement increase DA in the NAc and alter the firing 
of D2 MSNs [174]. Additionally, optogenetic inhibition of hypothalamic neurons 
reduces DA signals in the NAc, and also alters MSN firing [76].  
 
Given this level of sensitivity, it is plausible that the NAc may also respond strongly to 
changes in HCRTr1 signaling in the VTA. Acute HCRTr1 antagonism within the VTA 
appears to reduce the effects of cocaine, potentially through changes to NMDAr-
mediated excitability of dopaminergic neurons [26], and such manipulations also 
change the physiology of neurons that project to the NAc [163]. These types of 
alterations, which frequently change both dopamine release and uptake, have been 
previously shown to alter NAc MSN activity [174]. The potential downstream effects 
on MSNs represent a plausible mechanism through which HCRTr1 may influence 
behavior. During the course of many addictive processes, there is often a change in 
the expression of dopamine receptors [175], and on the corresponding physiology of 
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cells which contain them. MSNs are considered critical for associative conditioning 
[176] and motivated behavior [177], and such changes are likely to produce significant 
behavioral results.  
 
Viral specific approaches for examining the role of HCRT in motivated behavior 
 
Since the discovery of the hypocretin system, there has been a significant degree of 
research that links HCRT to dopaminergic function and reinforcement processing. 
However, there are important limitations to the current body of work. First, a  majority 
of studies which focus on HCRT utilize acute, often systemic manipulations to the 
HCRT system, and thus, much less is known about HCRT-driven effects on specific 
brain regions. Second, many of these manipulations utilize compounds that have off 
target effects, such as SB-334867 [178]. While the off-target effects are not 
overwhelming, their presence is large enough to potentially disrupt behavior, which 
can make it difficult to isolate the effects of HCRTr1 on behavior- and dopamine- 
specific paradigms.  Third, it is largely unknown how the system responds to long term 
alteration of HCRTr1 signaling. This is a critical point because addiction often portends 
long-term changes to neurotransmitter systems, and it has been shown that addictive 
processes can have sustained effects on HCRT function. Further, virtually all 
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pharmacological approaches in the rehabilitative setting have necessitated a non-
acute, long term program of treatment. Hence, it is critical to measure how HCRTr1 
manipulations can change the functioning of the dopaminergic system over an 
extended period of time. To our knowledge, this question has not been posed until 
the current research. For these reasons, we utilize an approach that relies on viral 
knockdown of the hypocretin 1 receptor, to assess the relationship between HCRTr1, 
dopamine signaling, and behavior. This approach offers several important advantages 
over other non-acute alternatives. 
 
Advantages and challenges of the viral knockdown technique 
 
Sustained HCRTr1 downregulation 
 
Viral knockdown allows for a more comprehensive investigation of the long-term role 
of HCRTr1. Critically, viral knockdown enables us to create a period of sustained 
downregulation of HCRTr1 signaling, without the disruptive effects of repeated 
injections, which have been shown to induce a strong stress response [179], and 
significantly affect reward-seeking behavior [180]. While this problem could be 
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somewhat circumvented by utilizing a permanently implanted catheter or cannula, the 
immediate presence of a human experimenter would still be a confounding factor 
during each infusion [181]. Furthermore, infusions given daily (either by needle or by 
implanted device) would still lead to a variable degree of HCRTr1 antagonism 
between injections, as opposed to the constant level of reduction level which would 
be attained from utilizing a more genetic approach.  
 
Greater receptor specificity 
 
Second, viral knockdown delivers a degree of receptor specificity that is beyond the 
capacity of current pharmacological approaches. Even the most commonly used 
compound for inducing HCRTr1 antagonism (SB-334867) produces discernable 
actions at the A2A adenosine receptor, the 5HT2A serotonin receptor, and even the 
HCRTr2 [178]. While this is not necessarily indicative of an inadequacy on the part of 
the SB-334867 compound to sufficiently target HCRTr1 (the compound does still have 
a strong specificity for HCRTr1 vs. HCRTr2) [182], it is evident that there are limitations 
of even the most receptor-specific pharmacological approach. By contrast, an 
appropriately constructed viral vector can achieve essentially perfect specificity for the 
targeted gene [183]. This is because the transgene being delivered is specific to only 
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one gene product, and as a result, transcription and translation of other gene 
products would not be affected [184]. 
 
 
Availability for use in genetically unmodified animals 
 
Finally, our technique offers the advantage of using wild-type animals, thereby 
avoiding the developmental alterations which are found to be present in genetically 
modified animals [185]. Knockout animals can demonstrate dramatic differences in 
dopamine function [123], and can also exhibit many differences in behavior [41]. As 
we are able to assess the role of HCRTr1 disruption in a more natural population, the 




It is important to note that even though this is meant to better assess the role of 
HCRTr1 over the course of cocaine addiction, we understand that virus injections are 
unlikely to be utilized as a direct therapeutic intervention in a rehabilitative setting. 
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However, utilizing a virus IS a crucial tool for measuring the long-term involvement of 
a neuropeptide system across a behavioral paradigm, without necessitating 
behaviorally disruptive injections of antagonists. Current experimental techniques, 
such as CRISPR, zinc-fingered nucleases, and others, can be used to create an 
extremely targeted approach, to manipulate virtually any aspect of the vector or the 
gene. Both methods are highly effective at driving the expression of only the specific 
target sequence, and the resulting product can then be amplified many times via 




The regional and receptor specificity gained by using viral knockdown, combined with 
the strongly diminished behavioral side effects of a viral approach [187] allow us to 
model HCRTr1 function in the VTA to a more precise extent than has been previously 
possible. This approach will therefore enable us to seek answers to our experimental 
questions with great clarity. First, we will be able to assess the long-term role of 
HCRTr1 in maintaining the dopamine system. Second, we can observe how long-term 
downregulation of HCRTr1 specifically in a dopamine-producing region can lead to 
changes in dopamine synthesis, dopamine release, dopamine uptake, and the 
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dopamine response to cocaine. As such, we can also critically evaluate the 
downstream effects of VTA-HCRTr1 knockdown on regions which receive significant 
dopaminergic input, such as the core of the NAc. 
 
Finally, viral knockdown will allow us to better assess the role of HCRTr1 in developing 
and maintaining motivation for cocaine reinforcement. Since this approach 
necessitates no maintenance dosing, and stays onboard for many weeks, we are able 
to assess how alteration of HCRTr1 in VTA can impacts the duration of time necessary 
to develop cocaine-motivated responding under a low-effort schedule. In the same 
animals, we are then able to measure the behavioral motivation for cocaine under a 
high-effort progressive ratio schedule, and determine how this may change over time. 
Our viral approach enables us to this without having to account for parallel effects 
from alterations to HCRTr2 or other receptors. Taken together, our viral knockdown 
approach offers much to advance our understanding of the HCRTr1 system and its 












The hypocretin / orexin (HCRT) system has been shown to modulate motivated 
behavior, likely via actions on the mesolimbic dopamine (DA) system. This 
neuroexcitatory peptide system sends extensive projections to numerous reward-
related regions, including the ventral tegmental area (VTA), which contains both HCRT 
receptor 1 and HCRT receptor 2 subtypes. HCRT appears to drive VTA DA cellular 
activity, increase DA responses to cocaine in the NAc (NAc), and promote cocaine 
self-administration behavior, while blockade of HCRTr1 produces opposite effects on 
these measures. While existing literature points to HCRTr1 as being important for 
regulating reinforcement processes, most studies have employed acute, 
pharmacological manipulations of HCRT signaling. Further, these studies have relied 
heavily on peripheral delivery of the HCRTr1 antagonist, SB-334867, which has been 
criticized for having off-target effects. Therefore, relatively little is known about the 
long-term, modulatory effects of HCRTr1 manipulation, or the specificity of actions on 
this receptor in the VTA. Consequently, employing viral knockdown of HCRTr1 within 
the VTA may address many of these shortcomings, thereby allowing us to specifically 
target the HCRTr1 in a region-specific manner, and to assess the consequences of 
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VTA-HCRTr1 knockdown on cocaine self-administration, DA release and reuptake in 
the NAc, cellular firing in the NAc, and the expression of proteins important for DA 
trafficking. Furthermore, subsequent usage of cell-specific viruses will enable further 
clarification of the effects of HCRTr1 on the dopaminergic and GABAergic 
components of the VTA, and allow for more specific conclusions to be drawn about 
downstream effects of HCRTr1 manipulation on regions which receive major 
projections from the VTA. Completing the proposed research will provide critical 
insights for the modulatory role of the HCRT system, and will lay important 
groundwork for the development of future HCRTr1-based pharmacotherapies. 
            
           
Specific Aim 1:  
 
To establish the methodology of viral knockdown of HCRTr1 in VTA, and to assess 
molecular effects of the viral treatment. Prior research has suggested that modulations 
of HCRTr1 function in the VTA can alter both motivated behavior and dopamine 
neurotransmission, in a bidirectional manner. However, the majority of such studies 
utilize acute and somewhat non-specific pharmacological approaches to examine the 
importance of HCRT signaling. Hence, little is known about the specific impact of 
prolonged downregulation of HCRTr1 in VTA on these measures. Our first aim is to 
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therefore develop and optimize a viral technique for inducing sustained knockdown of 
HCRTr1 in a region-specific manner, and to discern whether viral knockdown impacts 
the expression of other proteins related to dopamine neurotransmission.  We will also 
utilize qRT-PCR and immunohistochemistry to determine the efficacy and toxicity of 
the viral method, and optimize it as a technique. The experiments of aim 1 will 
critically evaluate and optimize viral knockdown as an effective experimental tool for 
assessing long term hypocretin function.  Hypothesis: Viral knockdown will prove to 
be an effective and nontoxic tool for inducing long term downregulation of HCRTr1. 
 
Specific Aim 2:  
 
To evaluate the effects of VTA-HCRTr1 knockdown on motivated behavior and 
dopaminergic signaling. Previous work has demonstrated that manipulations to HCRT 
signaling can influence dopaminergic signaling in the NAc, and can also induce 
profound effects on motivated behavior. These effects appear to be bidirectional, with 
reductions in HCRT leading to a reduction in behavior and dopamine release. 
However, these studies have utilized acute manipulations to HCRTr1 activity, and 
therefore cannot model the ongoing role of the HCRT system throughout the 
behavioral progression of addiction. Additionally, acute manipulations to HCRT cannot 
effectively model longer-term, physiological changes to the mesolimbic system. 
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Hence, we will investigate the effects of prolonged bilateral viral knockdown of VTA-
HCRTr1 expression on the acquisition of and continued motivation for cocaine self-
administration, using fixed- and progressive ratio schedules of reinforcement. 
Additionally, we will control for effects on arousal by recording sleep activity for 48 
hours in animals with viral knockdown. In addition, we will apply the method of viral 
knockdown to one hemisphere of the VTA, and evaluate changes in DA release and 
uptake in the NAc using voltammetry. These studies will provide crucial information 
about the specific role of VTA-HCRTr1 on the pursuit of cocaine-based rewards, the 
role of arousal in mediating this process, and the dopaminergic underpinnings of this 
relationship.  Hypothesis: VTA-HCRTr1 knockdown will delay acquisition of and reduce 
motivation for cocaine self-admin, and will reduce dopamine uptake and release, with 




Specific Aim 3 
 
To evaluate pre- and post-synaptic effects of TH-specific HCRTr1 knockdown. The 
initial two aims utilize a viral approach which targets all neurons of the VTA. However, 
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as HCRTr1 is located on many cell types in the VTA, it is currently unclear whether the 
effects of HCRTr1 manipulations involve cell types other than DA neurons, such as 
GABAergic neurons. Additionally, in order to better measure the effects of HCRTr1 on 
pre- and postsynaptic elements of DA neurotransmission, it is critical to utilize an 
approach that is specific to DA cells. Many observations indicate that changes to DA 
function can result in alterations to overall dopamine neurotransmission, which may 
have significant postsynaptic ramifications, such as with Medium Spiny Neuron (MSN) 
activity. Multiple studies indicate that the firing rate of MSNs is sensitive to the effects 
of drugs of abuse, including cocaine and to assess how HCRTr1-mediated effects on 
DA affect cellular firing in the NAc.  As the long-term, cell-specific effects of HCRTr1 
knockdown have not yet been explored, we elected to further investigate the effects 
of HCRTr1 knockdown on exclusively dopaminergic cells of the VTA. First, we apply 
these cell-specific approaches to both cell types, and compare the effect on the 
expression of overall levels of HCRTr1, DAT, TH, and VMAT, in the VTA. Upon the 
finding that only TH-specific viral knockdown induces significant alteration to overall 
VTA-HCRTr1 expression, we focused the remainder of the experiments on exclusively 
the dopaminergic cells of the VTA. To assess presynaptic effects we utilize an ex-vivo 
voltammetry preparation, to examine the effects of dopamine cell-specific HCRTr1 
knockdown on the release and reuptake of dopamine in NAc, in the presence of 
varying concentrations of cocaine. In addition to providing more clarity into the 
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presynaptic effects, we also perform an initial investigation of the postsynaptic DA 
environment. Specifically, we evaluate the effects of TH-specific HCRTr1 KD on the 
firing rate of medium spiny neurons, under baseline conditions and in response to 
cocaine. Together, this aim will clarify the effects of HCRTr1 knockdown on DA cellular 
function, and on MSN cellular activity in the NAc, and the extent to which such 
knockdown affects the physiological response to cocaine. Hypothesis: HCRTr1 
knockdown in the VTA, specific to DA neurons will decrease DA release and increase 
DA uptake in the NAc, and will also alter the firing rate and burst pattern of D1- and 



































Chapter 3: Establishing viral knockdown, and measuring molecular effects 
 
Abstract  
The Hypocretin/Orexin system has been shown to be a key participant in motivated 
behavior and dopamine neurotransmission. In particular, the hypocretin 1 receptor 
(HCRTr1) in the ventral tegmental area/VTA appears to drive drug-maintained 
responding, and substantially regulates the firing and release of dopamine from 
neurons in the mesolimbic system. However, current observations are largely limited 
to acute studies of HCRTr1 manipulation, which utilize mostly systemic experimental 
manipulations. Hence, less is known about the long-term, neuromodulatory role of 
HCRTr1 in the mesolimbic circuit. In order to better model how HCRTr1 can affect 
dopaminergic function and addictive processes over time we characterized the utility 
of long term, region-specific viral knockdown. Specifically, we utilize shRNA vectors to 
target the neurons of the VTA, and induce sustained, long-term downregulation of 
HCRTr1 expression in the region. We determine that this viral approach produces 
knockdown of HCRTr1, which persists for a sufficient duration to model multiple 
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elements of motivated behavior, but causes no toxic or peripheral effects. We observe 
that long-term viral knockdown does not induce significant neurotoxicity, and does 
not alter the cellular composition of the VTA, while producing minimal effects on the 
expression of dopaminergic proteins or other hypocretin receptors. These findings 
provide invaluable support that viral knockdown is an effective tool at studying long 
term HCRT function, while avoiding many of the experimental confounds associated 




HCRTs have been shown to be critical mediators of motivated behavior. For instance, 
reducing the activity of the HCRTr1/HCRTr1 antagonism lowers the motivation for 
cocaine [77, 80] and nicotine [188], and reduces preference and taking of ethanol [66] 
These effects appear to be bidirectional, as the HCRTr1 peptide can also increase 
reward seeking, particularly when delivered into the VTA [77]. In addition to the 
profound effects caused by acute manipulations to the HCRT system, hypocretins also 
appear to be developmentally important to motivated behavior. Genetic alterations to 
the HCRT system also reduce preference for cocaine-paired environments [185], and 
appear to delay acquisition for responding for food-based reinforcers [189]. 
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Additionally, genetic disruptions to the HCRT system can induce profoundly altered 
behavioral phenotype, even increasing the probability of attention deficit hyperactivity 
disorder/ADHD [190].  
 
While both the acute effects of HCRT manipulations, as well as the developmental 
importance of the HCRT system, have been well-modeled, less is known about the 
ongoing, neuromodulatory role of the HCRT system. This is a critical gap in the 
research, as many compounds which target the hypocretin system are currently being 
evaluated as potential long-term pharmacotherapies [40]. As most clinical treatments 
are being delivered over an extended period of time [191], it is critical to understand 
how long-term alterations to HCRT signaling can affect the reward system. 
Understanding such issues will be critical to developing more targeted future 
therapeutics, and for recognizing the ways in which prolonged modulations can lead 
to unexpected results. For instance, there is evidence that extended use of daily 
microinjections of HCRT-1 peptide can induce analgesic sensitization [192]. Further, 
repeated antagonism of HCRTr1 has been shown to change patterns of responding 
during cocaine self-administration [193].  Hence, it is critical to understand how long-
term alterations to HCRTr1 can affect behavior, and how closely acute modulations 




Unfortunately, most current methods for modeling the ongoing role of HCRT contain 
significant limitations. Use of the most common acute method (injection of the 
HCRTr1 antagonist, SB-334867) has been criticized because of possible off-target 
effects at the HCRT receptor 2 (HCRTr2), the A2a adenosine receptor, and 5-HT2a 
serotonin receptor [178, 194, 195]. Further, the use of repeated injections has been 
demonstrated to be acutely stressful [179], and may mask behavioral effects of 
treatments [180]. Additionally, compounds which are used to selectively target the 
HCRT system are often given systemically, and therefore less is known about the 
regional-specific effects of these treatments. Finally, developmental manipulations to 
the HCRT system, such as the utilization of genetic knockout or overexpression 
models, contain different limitations, such as the fact that they do not mirror natural 
populations. Hence, to effectively evaluate the ongoing role of HCRTr1 in the VTA, it is 
critical to develop a technique that produces sustained, regionally specific alterations 
to HCRTr1 levels, while using genetically normal animals. We believe that the 
technique of viral-induced receptor knockdown can potentially address all such issues. 
 






Adult (350-400 g), male Sprague-Dawley rats (Harlan Laboratories, Frederick MD) 
were housed on a reverse light/dark cycle and given ad-libitum access to food and 
water. Animals were pair-housed prior to receiving infusions of HCRTr1-shRNA-
AAV10 or SCRM-shRNA-AAV10 viruses and subsequently single-housed. All protocols 
and animal procedures were conducted in accordance with the National Institutes of 
Health (NIH) Guide for the Care and Use of Laboratory Animals under the supervision 
of the Institutional Animal Care and Use Committee at Drexel University College of 
Medicine. 
 
Viral vectors  
 
In order to assess the role of HCRTr1 in the VTA, we developed a viral approach to 
reduce the expression of HCRTr1 in cells which originate in that region. Briefly, we 
utilized shRNA viruses in order to reduce the expression of functional HCRTr1 on the 
cell surface of VTA. Vectors were created at the University of Buffalo, under the 
direction of Dr. Caroline E. Bass. In the current approach, we used a combination of 
viruses (which matched up with different regions of the HCRTr1 sequence), applied 
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together. This is because previous research indicates that utilizing such a 
combinatorial approach can induce a stronger combined effect [196].  
To induce generic viral knockdown, our treatment virus (HCRTr1-shRNA-AAV10), we 
utilized a combination of viruses (Fig. 2A) which produce shRNAs, driven by the 
mouse U6 promoter that targets and degrades the HCRTr1 mRNA. The vectors used 
have been previously shown to modulate the expression of target proteins [197]. To 
effectively attenuate HCRTr1 expression, we generated three HCRTr1 shRNAs that 
target the following HCRTr1 sequences: (TGGTGCGGAACTGGAAGCGA, 
TGGCGCGATTATCTCTATCCG, and TAGCCAATCGCACACGGCTCT), as previous 
research has shown that such a combinatorial approach can produce a stronger 
cumulative effect [198]. The shRNAs consist of 20 - 21 nucleotide target sequences, a 
loop sequence (ACTCGAGA) containing an XhoI site, and the antisense to the HCRTr1 
target sequence. In the scramble control virus, the shRNA does not target any known 
RNA sequence in the rat genome. The constructs also produce an enhanced green 
fluorescent protein (EGFP) which is driven by a human cytomegalovirus promotor 
(CMV). Both the CMV promotor and AAV2/10 capsid are highly selective for neurons, 
a finding which as has been previously reported [199]. Consequently, it is likely that 
the virus used here preferentially transfects neuronal cells of the VTA which include 
both DA and GABA neurons, as well as the relatively small population of glutamate 
neurons located in this region [200, 201]. It is important to note that HCRTr1 is 
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expressed in both DA and GABA neurons of the VTA [161, 163, 202], and thus 
HCRTr1 knockdown is predicted to reduce HCRTr1 expression in both of these 
neuronal subtypes. Lastly, it is likely that the virus used would only transfect the cells in 
the area of injection, as AAV2/10 is not transported in a retrograde fashion [203].  
 
Viral vector construction and delivery:  
 
In order to effectively deliver the viral vectors, animals were anesthetized with 
isoflurane, and placed in a stereotaxic frame, with the skull placed at an angle of zero 
degrees. This was achieved by adjusting the angle of the skull until lambda and 
bregma were present at the same dorsoventral coordinate[204]. Using a dremel, burr 
holes of ~1mm were drilled at points 5.2 mm caudal and 0.95mm lateral from 
bregma. A borosilicate injection probe, with an inner diameter of ~30uM, was then 
lowered into the hole, until reaching the VTA, which was defined as -7.7mm ventral to 
brain surface [205]. Upon reaching VTA, we waited a period of 5 minutes for the 
tissue to settle, and then infused the virus (es) into the VTA, over a period of 10 
minutes; as this timeframe has been extensively shown to be sufficient for adequate 
dispersion but does not deposit virus too far from the site of infusion. Following 
infusion, the virus was given an additional 5 minutes to finish dispersing, prior to 
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removal of the injection probe. The burr hole was then plugged with bone wax, and 
the scalp was then sutured closed and skin glue was applied to the incision site. To 
promote healing and prevent infection, the skin was kept moistened with saline 
throughout the duration of the procedure, and the close incision was covered with 
neopredef, a compound containing analgesic, antibiotic, and anti-inflammatory 
properties. Following surgery, animals were housed singly, administered ketoprofen (5 
mg/kg, s.c.) at 12 hr intervals for 36 hr. Figure 2B shows an example infusion location 
in the general region of the VTA.  
 
Animal sacrifice and dissection (qRT-PCR)  
 
Rats received infusion of HCRTr1-shRNA-AAV10 virus in one hemisphere of the VTA 
and SCRM-shRNA-AAV10 virus into the contralateral hemisphere. After 4 weeks of 
incubation, animals were anesthetized with isoflurane and rapidly decapitated. Brains 
were extracted over ice and placed into a matrix slicing guide on ice, with the ventral 
surface visible. Two coronal cuts were made, with the rostral cut at the caudal portion 
of the mammillary bodies, and the second cut made 2.0 mm caudal to the first, 
yielding a single slice (−4.4 to −6.4 mm A/P relative to bregma) encompassing the 
majority of VTA. The tissue comprising VTA was taken as the area ventrolateral to the 
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periaqueductal grey, ventral to the mesencephalic reticular nucleus, and medial to the 
substantia nigra (Figure. 2C). 
 
qRT-PCR 
Immediately following extraction, tissue was placed into 75 µl of RNAlater (Qiagen 
Inc., Valenia, CA, USA), and stored at −20° C until processing. Total RNA was purified 
as previously described [206], with resulting A260/A280 ratios between 1.88 and 2.19, 
indicating high purity. cDNA was reverse transcribed and qRT-PCR was conducted as 
described previously [206], using a StepOnePlus Real-Time PCR System (Applied 
Biosystems, Grand Island, NY). Expression of HCRTr1, HCRTr2, tyrosine hydroxylase 
(TH), vesicular monoamine transporter (VMAT), D2 DA receptor (D2R) and the DA 
transporter (DAT) were quantified relative to cyclophilin-A using the relative 
quantification method (ΔΔCT). Primers were designed with the NCBI Primer design 
tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/; [207], and obtained from 
Invitrogen (Grand Island, NY; Table I). 
 




At the conclusion of the viral incubation period, rats were anesthetized with 5% 
isoflurane and transcardially perfused with 140 ml saline, followed by 150 ml of 10% 
formalin in 0.01 M phosphate-buffered saline (pH 7.4). Brains were extracted and fixed 
in 10% formalin solution for a further 60 min, then placed in a solution of 30% sucrose 




Prior to cryosectioning, a tracking mark was made in the right lateral cortex for 
identification of hemispheres. Using a microtome, 40 µM coronal sections through the 
VTA were collected, and then stored in a solution of 0.1% sodium azide in 0.01 M 
PBS, at 4 °C. To identify the site of infusion, sections were incubated overnight with 
primary antibodies for EGFP (600-101-215, 1:10000, Rockland Antibodies, Gilbertsville, 
PA) and TH (#AB152, 1:2000, EMD Millipore, Temacula, CA) at 4 °C, followed by 
Alexa-fluor 488 donkey anti-goat (A11055, 1:1000, Life Technologies, Eugene, OR) 
and Alexa-fluor 594 donkey anti-rabbit (A21207, 1:1000, Life Technologies) secondary 
antibodies, respectively for 90 min at 20 °C. To determine cellular density in the 
transfection sites, sections were incubated with the NeuN primary antibody 
(ab104225, 1:5000, Abcam, Cambridge, MA), overnight at 4 °C, followed by biotin-SP-
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conjugated donkey anti-rabbit secondary antibody (#711-065-152, 1:1000, Jackson 
Labs, West Grove, PA) for 90 min at 20 °C, followed by 60 min with the Avidin-Biotin 
Complex (Vector Laboratories, Burlingame, CA), and 2-5 min with the DAB reagent 
(Vector Laboratories). Sections were mounted and coverslipped with fluorescent 
mounting medium (Vector Laboratories) or with Vectamount (Vector Laboratories).  
 
 
To examine whether virus infusions resulted in loss of neurons in the VTA, sections 
containing the VTA were captured at 200x magnification using SpotPro 5.1 Imaging 
software (Spot Digital, Taipei, Taiwan). Images were taken from the three rostrocaudal 
(+4.4, +5.2, and +6.0) aspects of VTA centered at approximately 7.7 mm ventral from 
top of brain and 0.9 mm lateral to midline. This approach resulted in images that 
encompassed an approximately 1.0 mm x 0.75 mm rectangular area that was 
bordered medially by midline, laterally by the substantia nigra, and dorsally by the 
medial reticular nucleus for rostral sections and the red nucleus for caudal sections. 










HCRTr1-shRNA-AAV10 successfully reduces HCRTr1 in VTA  
 
To assess the effectiveness of viral transfection, rats were injected intra-VTA with 
HCRTr1-shRNA-AAV10 (n=10) in one hemisphere and SCRM-shRNA-AAV10 (n=10) 
in the contralateral hemisphere, to allow comparison of HCRTr1 mRNA levels within 
an animal. Four weeks after virus injection, we observed that 0.5 µl infusions of either 
virus produced robust expression of EGFP in the VTA (Fig. 2b) with little encroachment 
into adjacent regions including the substantia nigra. Further, injections of HCRTr1-
shRNA-AAV10 produced significant knockdown of HCRTr1 receptor mRNA in the 
VTA, relative to SCRM-shRNA-AAV10 (HCRTr1 KD = 9.89 * 104 ± 7.5 * 105 au;  SCRM 
1.57 * 103 ± 9.5 * 105 au; t(20) = 3.31, p = 0.0042), which indicates that the viral 
approach successfully reduced HCRTr1 in the VTA (Fig. 3). Importantly, HCRTr1-
shRNA-AAV10 did not alter HCRTr2, TH, VMAT or D2R mRNA, suggesting that our 
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approach did not indiscriminately alter DA neurons. Although not significant, there 
was a notable decrease in DAT mRNA levels (t(20)  = 1.43,  p > 0.05). 
 
To assess for potential toxicity, a separate group of animals was transfected as 
described above (n=4 per virus). After 4 weeks of incubation, coronal sections 
containing VTA were immunostained for NeuN as an established measure of neuronal 
density, and TH as a marker of DA synthesizing neurons. As shown in Figure 4A and 
4B, HCRTr1-shRNA-AAV10 did not affect NeuN-immunoreactive (ir) cell counts in the 
VTA relative to SCRM-shRNA-AAV10 (HCRTr1 KD = 121.8 ± 9.8 cells; SCRM = 130.2 
± 13.2 cells; t(22) = .61, p = 0.22). Additionally, HCRTr1-shRNA-AAV10 did not affect 
TH-ir cell counts relative to SCRM-shRNA-AAV10 (HCRTr1 KD = 43.1 ± 4.1 cells; 
SCRM = 38.6 ± 5.3 cells; t(22) = 0.47, p = 0.25, (Figure 4C and 4D). Together these 
observations provide multiple lines of evidence that HCRTr1 knockdown is not 







Figure 2. Illustration of viral vector and infusion placement in the ventral tegmental 
area (VTA). (A) Constructs packaged into adeno-associated virus (AAV) to express 
short hairpin RNA (shRNA) targeting the HCRTr1 or scramble control sequences. Viral 
vectors were comprised of two non-coding AAV inverted terminal repeats (ITRs) 
flanking a cytomegalovirus (CMV) promoter that drives expression of the enhanced 
green fluorescent protein (EGFP), followed by combined intron/poly A sequences 
(intro-pA) derived from SV40 to enhance EGFP expression, and the U6 promotor to 
drive expression of the shRNA. Viruses differed only in the shRNA sequence used. (B) 
Representative photomicrograph depicting EGFP labeling resulting from injection of 
the HCRTr1 knockdown virus in the VTA. Arrow indicates midline. Scale bar is 0.25 
mm. (C) Illustration of injection locations across the rostrocaudal extent of the VTA. fr, 





Primer Sequence Concentration 
Cyclophilin-A 5′-GTGTTCTTCGACATCACGGCT-3′ (forward) 
5′-CTGTCTTTGGAACTTTGTCTGCA-3′ (reverse) 
200 nM 
HCRTr1 5′-GCGAGGTCCAGGGCTCACT-3′ (forward) 
5′-GCCTGGTACACCCAGATGCCG-3′ (reverse) 
100 nM 
HCRTr2 5′-GGCAGGACCGCTTCAAAACTGGTAT-3′ (forward) 
5′-CCCTCAGACCTCCAGCCAGGT-3′ (reverse) 
200 nM 
TH 5′-CCTTCCAGTACAAGCACGGT-3′ (forward) 
5′-TGGGTAGCATAGAGGCCCTT-3′ (reverse) 
100 nM 
VMAT 5′-AGTCTCTGCTGTCTTGCCAAC-3′ (forward) 
5′-TGGTCCAGTGAAGCTCACTTCT-3′ (reverse) 
200 nM 
D2R 5′-AGACGATGAGCCGCAGAAAG-3′ (forward) 
5′-GCAGCCAGCAGATGATGAAC-3′ (reverse) 
100 nM 




Table II. Primer sequences and concentrations used for quantitative real-time 









Figure 3. qRT-PCR results of nonspecific virus on VTA proteins. HCRTr1-shRNA-
AAV10 reduces HCRTr1  expression in the ventral tegmental area. (a) Shown are the 
mean ± standard error of the mean (SEM) of mRNA levels for HCRTr1, hypocretin 
receptor 2 (HCRTr2), tyrosine hydroxylase (TH), vesicular monoamine transporter 
(VMAT), D2 DAr (D2R), and dopamine transporter (DAT) in the VTA following injection 
of the scramble (SCRM-shRNA-AAV10; SCRM) or HCRTr1 knockdown (HCRTr1-




Figure 4. HCRTr1-shRNA-AAV10 does not alter Neun or TH cell counts in the VTA.  
(A) Example photomicrographs depicting NeuN staining in the VTA following injection 
of SCRM or KD virus. Left panel; 50x magnification image depicting the VTA regions 
used for NeuN-immunoreactive (ir) cell counts. Dashed rectangles indicate the regions 
used for analysis (see Methods and Materials). Right panels; 200x representation of 
the dashed rectangular regions shown in the left panel. (B) Shown are mean ± SEM 
average number of NeuN-ir cells in the VTA. (C) Example photomicrographs depicting 
TH staining in VTA following injection of SCRM or KD virus. Left panel; 50x 
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magnification image depicting the VTA regions used for TH-ir cell counts. Dashed 
rectangles indicate the regions used for analysis (see Methods and Materials). Right 
panels; 200x representation of the dashed rectangular regions shown in the left panel. 
(D) Shown are mean ± SEM average number of TH-ir cells in the VTA. RN, red 








In the current studies, we determined that viral knockdown is an effective technique 
for inducing sustained downregulation of HCRTr1 specifically in the neurons of the 
VTA. We demonstrate that this method produces no discernable neurotoxic effects, 
and is effective at reducing HCRTr1 expression for a minimum of 4 weeks. 
Furthermore, we determine that our method of delivery produces expression that is 
spatially confined to the VTA, and functionally confined to neurons. Finally, we 
observe minimal effects on the expression of most dopamine-associated mRNAs.  
 
Previously, our laboratory has utilized acute manipulations to investigate the 
relationship between HCRTr1, dopamine signaling, and motivated behaviors. 
However, these studies have relied on acute dosing with compounds that induce a 
transient increase or decrease in HCRTr1 activity [80], and therefore do not uncover 
information about the ongoing neuromodulatory role of HCRTr1. While acute HCRTr1 
antagonism is a useful method for determining short term effects of HCRTr1 
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modulation, it would likely be a poor candidate for use in a chronic study for two 
reasons. First, tolerance to many compounds, including HCRT compounds, may 
develop [83]. Second, repeated injections cause an increase in the stress response 
[208] in rats, thereby complicating behavioral assessment. As stress itself can lead to a 
further reduction in HCRT signaling [209], it is critical to minimize the external effects 
of the method used to reduce HCRTr1 activity. Using viral knockdown ensures that 
only one treatment is given, and the animals are otherwise undisturbed, creating a 
more natural modeling of the effects.  
 
We also determine that this method of viral knockdown is essentially nontoxic, as 
there are no significant changes to cell density caused by viral knockdown, compared 
with the scramble control virus. Further, TH+ cell counts are unaffected, indicating that 
our viral method does not substantially alter the cellular composition of the targeted 
area.  Such findings bode well for our future investigations, where we will apply viral 
knockdown in order to assess long-term changes to dopamine signaling and 
motivated behavior. As the viruses only lead to the production of shRNAs which 
interfere with HCRTr1 expression, and not any viral protein (other than GFP), the 




Importantly, there was no observed reduction in HCRTr2 expression. As previously 
discussed, HCRTr1 and HCRTr2 share a strong degree of structural homology [5], and 
using a HCRT-specific viral technique presented a risk of nonspecific knockdown of 
HCRTr2 expression. After observing no significant effect on HCRTr2 expression, we 
can confidently conclude that our viral vectors confer a strong degree of specificity, 
and are not likely to directly interfere with the expression of other proteins.  
 
In addition to conferring a strong degree of specificity to the gene being targeted, our 
method of viral knockdown can also be modulated by changing other aspects of the 
viral construct. For instance, the serotype (capsid packaging) of the virus, can be 
modified, in order to determine spread and cell type targeted [210]. For instance, we 
utilize an adeno-associated virus with a serotype of 10, which is highly specific for 
neurons [211], and contains a limited degree of physical spread, likely ensuring that 
most viral delivery remains in VTA [212]. In addition, the promoter region can be 
modified to further favor delivery to only a specific cell type [211]. While glia do 
possess a small degree of HCRTr1 expression on their cell surface; [213], our viral 
vector is not likely to produce significant effects on these cells because of the type of 
promoter used. Combined with a meticulous verification of injection coordinates, our 
technique of viral knockdown offers the precise ability to target HCRTr1 expression in 




Finally, viral knockdown offers the advantage of being able to evaluate long term 
changes to cellular functioning, related to the HCRT system. Previous research has 
indicated that VTA-HCRTr1 may confer a strong degree of influence on dopaminergic 
signaling. First, HCRTr1 is a strong regulator of PKC signaling [214], which can drive 
the expression [215] and relative activity of proteins that are critical for the production 
and transport of dopamine, such as tyrosine hydroxylase [216], the dopamine 
transporter [212], and DAr 2 [217]. Second, HCRTr1 activity has been shown to 
modulate the excitability of VTA cells [26], and there are indications that long term 
downregulation of HCRTr1 signaling can confer long term changes to cellular 
morphology [218]. Hence, viral knockdown offers the opportunity to model long term 
changes in the functionality of VTA cells, following sustained disruption of local 
HCRTr1 function. This research will go a long way towards understanding the 
molecular mechanisms through which hypocretin can modulate dopamine 
neurotransmission, and may offer key insights for future studies into potential 
addiction pharmacotherapies.  
 
We evaluate the effects of the virus over an extended duration and determine the 
timeline of peak effects. We also assess for molecular effects on protein and mRNA 
expression over the course of the experiment. These experiments will help to establish 
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the technique of viral knockdown for assessing HCRTr1 function, and evaluate its 
feasibility for use in the types of behavioral and neurochemical experiments which 
have previously been used to determine much of what is currently known about HCRT 
function.  
 
In summary, we successfully pioneer the technique of viral knockdown of HCRTr1. We 
are the first lab to apply this technique to the ventral tegmental area, and the first to 
assess its effects on dopaminergic signaling. This research lays important groundwork 
for future planned experiments, which will explore the role of VTA-HCRTr1 in 
dopaminergic signaling and motivated behavior. Taken together, these findings 
represent an important first step towards the modeling of the long-term role of 
HCRTr1 in the VTA, and pave the way for future studies to more comprehensively 















The HCRTr1 is a critical participant in the regulation of motivated behavior. Previous 
observations demonstrate that acute pharmacological blockade of HCRTr1 disrupts 
dopamine (DA) signaling and the motivation for cocaine when delivered systemically 
or directly into the ventral tegmental area (VTA). To further examine the involvement 
of HCRTr1 in regulating reward and reinforcement processing, we employed an 
adeno-associated virus to express a short-hairpin RNA designed to knock down 
HCRTr1. We injected virus into the VTA and examined the effects of HCRTr1 
knockdown on cocaine self-administration and DA signaling in the NAc (NAc) core. 
We have previously determined that the viral approach was effective at reducing 
HCRTr1 expression without inducing many changes to the expression of dopamine-
related mRNA or inducing toxicity. We therefore applied the method of viral 
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knockdown to examine the effects of long term HCRTr1 downregulation on cocaine 
self-administration. We observed delayed acquisition under a fixed-ratio schedule, 
and reduced motivation for cocaine under a progressive ratio schedule. These effects 
did not appear to be associated with alterations in sleep/wake activity, which we 
assessed using 24-hour recordings of freely moving EEG and EMG activity. Finally, we 
used fast scan cyclic voltammetry to examine whether HCRTr1 knockdown alters DA 
signaling dynamics in the NAc core. We observed reduced DA release and slower 
uptake rate as well as attenuated cocaine-induced DA uptake inhibition in rats with 
knock down of HCRTr1. These observations indicate that HCRTr1 within the VTA 




The hypocretin/orexin (HCRT) neuropeptide system is recognized to influence 
arousal-related processes [219-222]. Although initially identified for its participation in 
governing sleep/wake function, HCRT is increasingly recognized to influence reward 
and reinforcement [60, 223-226]. For example, infusions of HCRT-1 peptide increase 
self-administration of cocaine [58], increase alcohol consumption [59], and reinstate 
food-based responding [60]. Furthermore, systemic or ventral tegmental area (VTA) 
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delivery of the HCRT receptor 1  antagonist, SB-334867, reduces cocaine self-
administration [63, 67, 69, 71, 227, 228], reinstatement of cocaine seeking [225], and 
alters conditioned place preference for morphine [75]. These bidirectional effects of 
HCRT manipulations are consistent with the effects of genetic disruption of HCRT 
neurotransmission, as animals with complete knockout of HCRT peptides display 
reduced preference for morphine [75, 229] and cocaine [185], and mice with 
constitutive knock out of HCRTr1 receptors show diminished cocaine self-
administration [73]. Together, these observations indicate that the HCRT system exerts 
a prominent influence on reward and reinforcement. 
 
The behavioral effects of HCRT manipulations appear to be mediated, in part, through 
actions on the mesolimbic dopamine (DA) system. HCRT neurons send robust 
projections to the VTA [230, 231], where HCRT has been shown to potentiate 
excitatory drive and induce burst firing of DA neurons [26, 232]. Furthermore, intra-
VTA infusions of HCRT-1 peptide increase DA in the NAc core under baseline 
conditions, and promote DA responses to cocaine [58]. Consistent with these effects, 
systemic HCRTr1 blockade via SB-334867 reduces baseline and psychostimulant-
induced increases in DA signaling in the NAc [67, 69, 162, 165]. Further, intra-VTA 
infusion of SB-334867 decreases excitation of DA neurons [27] and disrupts DA 
responses to cocaine [67]. Finally, HCRT knockout mice display disrupted DA signaling 
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in the NAc core under baseline conditions and following cocaine [185]. Together, 
these observations provide strong evidence for HCRT involvement in the regulation of 
mesolimbic DA signaling that may underlie observed effects on cocaine 
reinforcement. 
 
The majority of studies which assess HCRTr1 involvement in reward and reinforcement 
have employed acute, often systemic pharmacological manipulations to HCRT 
signaling. While this has yielded significant advancements in our understanding of 
HCRTr1 function, potential issues related to receptor and site specificity exist. For 
instance, SB-334867 has been criticized because of hydrolytic instability and possible 
off-target effects at the HCRT receptor 2 (HCRTr2), the A2a adenosine receptor, and 
5-HT2a serotonin receptor [178, 194, 195]. In addition, most pharmacological 
manipulations of HCRTr1 are systemic, and therefore do not provide information 
about the contributions of particular brain regions, such as the VTA. To circumvent 
receptor specificity issues, and to evaluate the importance of the VTA in modulating 
HCRT effects on behavior, we injected a short-hairpin RNA (shRNA) virus designed to 
knock down HCRTr1 mRNA (HCRTr1-shRNA-AAV10) directly in the VTA. In addition 
to allowing for specific targeting of HCRTr1, the viral approach also enabled us to 
examine the effects of sustained disruption of HCRTr1 on the regulation of cocaine 
self-administration and DA signaling. We evaluated the effects of the HCRTr1-shRNA-
75 
 
AAV10 virus or the scramble control virus (SCRM-shRNA-AAV10), on the acquisition 
and maintenance of cocaine self-administration by using a combination of fixed ratio 
(FR) and progressive ratio (PR) schedules of reinforcement. We next assessed the 
effects of HCRTr1 knockdown on sleep/wake activity, to confirm that HCRTr1 
manipulations do not produce gross deficits in arousal. Finally, to examine whether 
the effects of HCRTr1 knockdown on behavior are associated with alterations in DA 
signaling, we used in vivo fast scan cyclic voltammetry (FSCV) to examine DA release 
and uptake dynamics in the NAc core. 
 
MATERIALS AND METHODS 
 
Viral vectors and infusions  
 
In order to assess the role of HCRTr1 in the VTA, we developed a viral approach to 
reduce the expression of HCRTr1 in cells which originate in that region. Briefly, we 
utilized shRNA viruses in order to reduce the expression of functional HCRTr1 on the 
cell surface of VTA. Vectors were created at the University of Buffalo, under the 
direction of Dr. Caroline E. Bass. In both approaches, we used a combination of 
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viruses (which matched up with different regions of the HCRTr1 sequence), applied 
together. This is because previous research indicates that utilizing such a 
combinatorial approach can induce a stronger combined effect [198, 233].  
 
To induce HCRTr1 knockdown, (HCRTr1-shRNA-AAV10), we utilized a combination of 
viruses which produce shRNAs, driven by the mouse U6 promoter that targets and 
degrades the HCRTr1 mRNA. The vectors used have been previously shown to 
modulate the expression of target proteins [197]. To effectively attenuate HCRTr1 
expression, we generated three HCRTr1 shRNAs that target the following HCRTr1 
sequences: (TGGTGCGGAACTGGAAGCGA, TGGCGCGATTATCTCTATCCG, and 
TAGCCAATCGCACACGGCTCT), as previous research has shown that such a 
combinatorial approach can produce a stronger cumulative effect [198]. The shRNAs 
consist of 20 - 21 nucleotide target sequences, a loop sequence (ACTCGAGA) 
containing an XhoI site, and the antisense to the HCRTr1 target sequence. In the 
scramble control virus, the shRNA does not target any known RNA sequence in the rat 
genome. The constructs also produce an enhanced green fluorescent protein (EGFP), 
which is driven by a human cytomegalovirus promotor (CMV). Both the CMV 
promotor and AAV2/10 capsid are highly selective for neurons, a finding which as has 
been previously reported [199]. Consequently, it is likely that the virus used here 
preferentially transfects neuronal cells of the VTA which include both DA and GABA 
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neurons, as well as the relatively small population of glutamate neurons located in this 
region [200, 201]. It is important to note that HCRTr1 is expressed in both DA and 
GABA neurons of the VTA [161, 163, 202], and thus HCRTr1 knockdown is predicted 
to reduce HCRTr1 expression in both of these neuronal subtypes. Lastly, it is likely that 
the virus used would only transfect the cells in the area of injection, as AAV2/10 is not 
retrogradely transported [203].  
 
Viral vector construction and delivery 
In order to effectively deliver the viral vectors, animals were anesthetized with 
isoflurane, and placed into a stereotaxic frame with the skull placed at zero degrees. 
This was achieved by adjusting the angle of the skull until lambda and bregma were 
present at the same dorsoventral coordinate. Using a dremel, burr holes of ~1mm 
were drilled at points 5.2 mm caudal and 0.95mm lateral from bregma. A borosilicate 
injection probe, with an inner diameter of ~30uM, was then lowered into the hole, 
until reaching the VTA, which was defined as -7.7mm ventral to brain surface[205]. 
Upon reaching VTA, we waited a period of 5 minutes for the tissue to settle, and then 
infused the viruses into the VTA, over a period of 10 minutes; as this timeframe has 
been extensively shown to be sufficient for adequate dispersion but does not deposit 
virus too far from the site of infusion. Following infusion, the virus was given an 
additional 5 minutes to finish dispersing, prior to removal of the injection probe. The 
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burr hole was then plugged with bone wax, and the scalp was then sutured closed 
and skin glue was applied to the incision site. To promote healing and prevent 
infection, the skin was kept moistened with saline throughout the duration of the 
procedure, and the close incision was covered with neopredef, a compound 
containing analgesic, antibiotic, and anti-inflammatory properties. Following surgery, 
animals were housed singly, administered ketoprofen (5 mg/kg, s.c.) at 12 hr intervals 
for 36 hr.  
  
 
Immunohistochemistry and cell counting 
 
At the conclusion of all experiments, rats were anesthetized with isoflurane and 
transcardially perfused with 140 ml saline, followed by 150 ml of 10% formalin in 0.01 
M phosphate-buffered saline (pH 7.4). Brains were extracted and fixed in 10% 
formalin solution for a further 60 min, then placed in a solution of 30% sucrose in PBS 
for 72 hr at 4 °C. Prior to cryosectioning, a tracking mark was made in the right lateral 
cortex for identification of hemispheres. Using a microtome, 40 µM coronal sections 
through the VTA were collected, and then stored in a solution of 0.1% sodium azide 
in 0.01 M PBS, at 4 °C. To identify the site of infusion, sections were incubated 
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overnight with primary antibodies for EGFP (600-101-215, 1:10000, Rockland 
Antibodies, Gilbertsville, PA) and TH (#AB152, 1:2000, EMD Millipore, Temacula, CA) 
at 4 °C, followed by Alexa-fluor 488 donkey anti-goat (A11055, 1:1000, Life 
Technologies, Eugene, OR) and Alexa-fluor 594 donkey anti-rabbit (A21207, 1:1000, 
Life Technologies) secondary antibodies, respectively for 90 min at 20 °C.  
 
To determine the magnitude and location of viral expression, EGFP labeled cells were 
counted in the VTA and adjacent structures across the anterior (+4.4 mm), central 
(+5.2 mm), and posterior (+6.0 mm) aspects of VTA, relative to bregma. Counts were 
performed by an experimenter blinded to treatment conditions under 200x 
magnification using on an Axiovert 135m fluorescence microscope (Zeiss Instruments, 
Thornwood NY). To be included in analyses rats had to display; 1) an average count 
of at least 100 EGFP-labeled cells in each hemisphere of the VTA across the 3 rostro-
caudal sections sampled; and 2) at least 75% of all EGFP-labeled cells had to be 
located in the VTA as opposed to adjacent structures.  
 




 Rats received unilateral infusion of either HCRTr1-shRNA-AAV10 or SCRM-shRNA-
AAV10 into the VTA. After 4 weeks of incubation, rats were anesthetized with 
isoflurane, implanted with an acute jugular catheter, and placed in a stereotaxic frame. 
Rats were implanted with a bipolar stimulating electrode (Plastics One) in the VTA 
(+5.2 mm A/P, +1.1 mm M/L, −7.5 to −8.0 mm D/V), a carbon fiber microelectrode in 
the core of the NAc (−1.3 mm A/P, +1.3 mm M/L, −6.5 to −7.0 mm D/V), and a 
reference electrode in the contralateral cortex (−2.5 mm A/P, −2.5 mm M/L, −2.0 mm 
D/V). Monophasic electrical pulse trains (60 Hz, 4 ms, 600 mA, 60 pulses) in the VTA 
were used to evoke DA release in the NAc, in accordance with established methods 
[69, 162]. During baseline recordings, electrically-evoked DA release was elicited every 
5 min for a minimum of 30 mins or until a stable baseline recording was obtained (DA 
release within 10% across three consecutive stimulations). After obtaining 15 min of 
stable baseline recordings, animals received a 2 s, ~200 µl i.v. cocaine injection (1.5 
mg/kg). The 1.5mg/kg dose of cocaine was used to compare with previous FSCV 
studies [67, 69, 77, 162] and because this dose produces sufficient DA uptake 
inhibition [234] to assess reductions in cocaine effects following disruptions to HCRTr1. 
Electrically-evoked DA release was elicited 30 sec, 1 min, and 5 min post cocaine 
delivery, and every 5 min thereafter for 60 min. The electrode potential was linearly 
scanned (−0.4 to 1.2 V and back to −0.4 V vs Ag/AgCl) and cyclic voltammograms 
were recorded every 100 ms with a scan rate of 400 V/s using a 
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voltammeter/amperometer (Chem-Clamp; Dagan Corporation, Minneapolis, MN). 
Quantification of electrically-evoked DA release was achieved by comparing current at 
the peak oxidation potential for DA in consecutive voltammograms with calibration 
factors obtained from electrodes exposed to 3 μM DA. DA overflow curves were fitted 
to a Michaelis-Menten-based kinetic model using Demon Voltammetry and Analysis 
software [235] written in LabVIEW language (National Instruments, Austin, TX). DA 
uptake rates prior to cocaine delivery were modeled by setting the affinity of DA for 
the DA transporter (DAT) between 0.16 – 0.20 μM and then fitting the overflow curve 
to establish a baseline, maximal uptake rate (Vmax) for each subject. Baseline release 
and uptake were expressed as the average of 3 collections that occurred prior to the 
injection of cocaine. Following cocaine injection, Vmax was held constant for the 
remainder of the experiment and changes in DA uptake rate due to cocaine-induced 
uptake inhibition were calculated as a change in the apparent affinity for the DAT and 




Animals were infused intra-VTA with the combination of the 3 HCRT knockdown 
viruses. Control animals were given the nonspecific scramble virus, which only 
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encoded for a green fluorescent (GFP) product. Immediately following extraction, NAc 
and VTA tissue were flash frozen in dry ice. Dissected VTA was placed into RNAlater 
and reserved for qRTPCR experiments, while NAc tissue was kept for western blotting 
experiments. Brain tissue was then digested with proteinase K in membrane prep 
buffer (250 mM sucrose, 1 mM EDTA, 10 mM Tris HCl), and homogenized with beads 
(Fisher, #15340153) for 40 seconds. Following 10 min of centrifuging at 4 degrees and 
1000rpm, the supernatant was extracted, and stabilized with 10% DTT. Following the 
Pierce BCA protein quantification assay (MAN0011430, Thermofisher Scientific), 
samples were accordingly diluted to contain 100ug protein in 100ul. 10ug of protein 
was then loaded into each well of 4%–12% Tris-Glycine gels. Samples were subjected 
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for a 
period of 1 hour at ~200V. All proteins were transferred to nitrocellulose membranes 
and then blocked for 1 h at room temperature with blocking medium [142 PI37515]. 
The membranes were then probed with either rabbit monoclonal DAT primary 
antibody (1:1000, overnight at 4 °C) (AB2231; EDM Millipore, Billerica, MA, USA), 
rabbit polyclonal primary TH antibody (1:1000, overnight at 4 °C) (AB152, EDM 
Millipore), rabbit polyclonal primary TH- Ser31 antibody (1:1000, overnight at 4 °C) 
(AB5423, EDM Millipore), rabbit polyclonal primary TH-Ser40 antibody (1:1000, 
overnight at 4 °C) (#2791, Cell Signaling) or rabbit polyclonal primary VMAT-2 
antibody (1:1000, overnight at 4 °C) (AB1598P, EDM Millipore), with mouse 
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monoclonal Actin primary antibody (1:2000, overnight at 4 °C) used as a control. All 
incubations with primary antibodies were followed by washing with PBS-Tween (HRP)-
conjugated secondary antibodies (1:10,000, 1 h at room temperature). Blots were 
assayed for fluorescence at the 700nm and 800nm wavelengths, using the LI-COR 
system. For standardization across blots, each blot contained all experimental groups. 
The western blot data was expressed as relative optical density of HCRT KD tissue 
normalized to saline controls. This approach normalized differences in the 
development of the blot and across multiple runs of sample. All western blotting was 
performed in accordance with standard protocol [236]. 
 
Jugular vein catheters 
 
Rats were anesthetized with ketamine [236] and xylazine (10 mg/kg) and implanted 
with an intravenous [236] silastic catheter (ID, 0.012 in OD, 0.025 in. Access 
Technologies, Skokie, IL) in the right jugular vein that exited through the skin of the 
dorsal scapulae region. The catheter also contained hernia mesh to facilitate 
permanent implantation. The catheter was connected to tubing enclosed by a 







Rats received bilateral infusions of either the HCRTr1-shRNA-AAV10 or SCRM-shRNA-
AAV10 viruses into the VTA. After 2 weeks of incubation, rats were anesthetized with a 
ketamine/xylazine (80/10 mg/kg, i.p.), and implanted with jugular catheters as 
previously described [69, 80, 228]. Immediately following surgery, rats were placed in 
operant behavioral chambers, where they were housed for the duration of the 
experiments. On the third day after surgery, rats were placed on a FR1 schedule of 
reinforcement, whereby single lever presses resulted in delivery of 0.75 mg/kg 
intravenous (i.v.) cocaine (in saline; National Institute on Drug Abuse). Rats were given 
6-hr daily access to a lever, and allowed a maximum of 20 injections per session. 
Following acquisition of self-administration (10 injections per session for 3 consecutive 
days), rats were allowed to self-administer on the FR1 schedule until they reached 
stable responding (3 days of 20 injections per session). The latency to first cocaine 
injection and rate of intake were monitored during these sessions. Rats were then 
switched to the PR schedule of reinforcement, with 6-hr access to a lever, and single 
cocaine (0.75 mg/kg) injections now contingent upon an increasing number of 
responses [237]. The 0.75mg/kg dose was selected because it is on the ascending 
limb of the “inverted-U” dose-response curve under the PR schedule [237] and to 
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compare to previous observations [69, 80, 238]. Average breakpoint (number of 
cocaine injections received per session without an intervening 1 hr break), and total 
lever presses were recorded for 10 days. The timing of catheterization surgeries and 
behavioral training were selected to ensure that rats were self-administering under the 




Rats received bilateral infusion of either HCRTr1 KD or SCRM viruses. Following 3 
weeks of bilateral viral incubation, rats were anesthetized with isoflurane, and placed 
into a stereotaxic frame. After administering local analgesia, the scalp was opened, 
and three screw electrodes (Plastics One, Roanoke VA), were implanted ~1mm into 
the skull. Screws were placed over NAc (+1.3mm lateral, +1.3mm anterior to bregma), 
hippocampus (+3.2mm lateral, -2.7mm posterior), and contralateral NAc (-1.3mm 
lateral, 1.3mm anterior). Additionally, two EMG wire electrodes were implanted into 
the dorsal neck muscle. EMGs were made using a 100mm length of insulated stainless 
steel wire (Cooner Wire, Chatsworth CA), soldered to a gold pin connector, with ~2 
mm of the wire stripped of insulation to allow for direct contact with the muscle tissue. 
All electrodes were routed through a 6-channel connector (Plastics One), and 
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cemented into place on the skull. Animals were given an additional week to recover 
from surgery. After recovery, rats were placed into the 16x16x24” sleep recording 
chamber with clean bedding, food, and a water bottle, and then connected to an 
electrophysiology headstage. After an initial 16 hr acclimation period, baseline EEG 
(0.3–100.0 Hz bandpass) and EMG signals (1.0–50.0 Hz bandpass) were amplified, 
filtered, and recorded using Labchart 7 (AD Instruments) for a period of 48 hr. Data 
was then post-processed in Labchart 7, and analyzed for using Sirenia Sleep Pro. All 
parameters to define waking, non-REM sleep, and REM sleep were defined previously 
[228]. 
 
Sacrifice and perfusion 
 
At the conclusion of the behavioral and neurochemical experiments, rats were 
anesthetized with 5% isoflurane until cessation of breathing. Animals were then 
transcardially perfused (with all fluids delivered to the left ventricle, and exiting out of 
the cut right atrium) and transcardially perfused with 140 ml saline, followed by 150 ml 
of 10% formalin in 0.01 M phosphate-buffered saline (pH 7.4). Saline was delivered at 
an initial rate of 20ml per minute, and formalin was delivered at a rate of 15ml/min for 
the first 5 minutes, and 10ml/min thereafter. The skull and dura were carefully 
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removed, and brains were placed in a 10% solution of formalin in PBS for an 
additional 60 minutes at room temperature. After 1 hour had elapsed, brains were 
then transferred to a solution of 30% sucrose in PBS for 72 hr at 4 °C, prior to 
cryosectioning and immunohistochemistry. 
 
Data analysis  
 
Acquisition of cocaine self-administration, time to first injection, and rate of intake 
were analyzed using independent student’s t-test to compare between virus 
treatments. The overall effects of HCRTr1 knockdown on motivation were assessed 
using a mixed design repeated-measures ANOVA, with viral treatment as the 
between-subjects variable and days as the within-subjects variable. Independent 
student’s t-test were conducted to compare the effects of viral treatment on time 
spent in each sleep/wake state and to measure differences in DA release and uptake 
(Vmax) prior to cocaine in FSCV experiments. Stimulated DA release, DA per pulse 
[DAp] and cocaine-induced DA uptake inhibition (Km) across the course of the 
experiment were assessed using mixed design, repeated measures ANOVAs with viral 
treatment as the between-subjects variable and time as the within-subjects variable. 
Planned comparisons for each of these DA measures were conducted using 
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independent student’s t-tests during the first 15 min following cocaine delivery based 
on previous observations indicating significant effects of HCRT manipulations on DA 
signaling at those time points[68, 77, 80]. Planned comparisons were not conducted 




We evaluated the effects of viral knockdown on behavior and dopamine 
neurotransmission. Initially, we evaluated both measures at the 2 and 4 week time 
point. However, because we did not see significant effects at the 2 week time point, 
we focused the majority of the experiments (and the majority of the animal resources) 
on the 4 week time points. Consequently, the results which follow are all evaluated at 
4 weeks post-transfection. The behavioral and neurochemical experiments at the 2-
week time point are described in the supplemental materials at the end of the 
document.  
 
HCRTr1 knockdown disrupts cocaine self-administration 
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To examine the involvement of HCRTr1 in the VTA on cocaine self-administration, rats 
received HCRTr1-shRNA-AAV10 (n=7) or SCRM-shRNA-AAV10 (n=6) bilaterally into 
the VTA. After 2 weeks of incubation, animals were implanted with jugular catheters 
and placed on an FR1 schedule to acquire cocaine self-administration (Figure 5A). As 
shown in Figure 5B, HCRTr1 knockdown significantly delayed acquisition of cocaine 
self-administration, relative to scramble controls (t (11) = 2.27, p = 0.044). Further, as 
shown in Figure 5C and 5D, no differences were observed between virus treatments 
for latency to first lever press (t(11) = 0.44, p = 0.62) nor the rate of cocaine intake (t(11) 
= 0.51, p = 0.52). Following testing on the FR1 schedule, rats were switched to a PR 
schedule to assess HCRTr1 knockdown effects on motivation for cocaine. As indicated 
in Figure 5E, over the 10 days of testing, HCRTr1 knockdown produced significantly 
lower breakpoints relative to scramble controls. Two-way repeated measures ANOVA 
indicated a significant effect of viral treatment (F(1,11) = 5.5, p = 0.039) but no 
significant effect of time (F(9,99) = 0.425, p = 0.92) or treatment X time interaction (F(9,99) 
= 0.649, p = 0.753). The total number of lever presses was not significantly different 






 Figure 5. HCRTr1 knockdown delays acquisition of cocaine self-administration and 
reduces motivation for cocaine. (A) Timeline of surgical procedures and experimental 
testing. Shown are the mean ± standard error of the mean for (B) number of days 
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required to reach acquisition criteria, (C) latency to first lever press, and (D) intake rate 
(i.e., injections/hr) under a fixed-ratio 1 schedule of reinforcement for rats treated with 
scramble (SCRM-shRNA-AAV10; SCRM) or HCRTr1 knockdown (HCRTr1-shRNA-
AAV10; KD) virus. (E) Shown are the mean ± standard error of the mean for 
breakpoints across the 10-day progressive ratio schedule for SCRM and KD animals. 




HCRTr1 knockdown does not alter arousal 
To examine whether the effects of HCRTr1 knockdown on self-administration were 
associated with alterations in sleep/wake activity, rats received SCRM-shRNA-AAV10 
or (n=6) or HCRTr1-shRNA-AAV10 (n=6) bilaterally into the VTA. After 3 weeks of 
incubation, rats were implanted with EEG/EMG electrodes, and then after 1 week of 
recovery, sleep/wake activity was recorded for 24 hr. As shown in Figure 6B, HCRTr1 
knockdown did not affect total time spent in waking (t(10) = 1.23, p = 0.25), NREM (t(10) 
= 0.57, p = 0.58) or REM sleep (t(10) = 1.05, p = 0.32). Further, no differences were 
observed between virus treatment on the number (waking: t(10 ) = 0.42, p = 0.66; 
NREM: t(10) = 0.36, p = 0.73; REM: t(10) = .62, p = 0.55) (Figure 6C) or duration (waking 
t(10 ) = 0.13, p = 0.91; NREM: t(10) = 0.52, p = 0.61; REM: t(10) = 0.42, p = 0.68) of 
sleep/wake bouts (Figure 6D). These results suggest that the behavioral effects of 















Figure 6. HCRTr1 knockdown does not alter sleep/wake behavior. (A) Representative 
trace of electroencephalographic/electromyographic recordings for bouts of NREM, 
REM, and waking.  (B) The mean ± standard error of the mean for total time spent in 
waking, non-rapid eye movement (NREM) and rapid eye movement [178] sleep for 
rats treated with the scramble (SCRM-shRNA-AAV10; SCRM) or HCRTr1 knockdown 
(HCRTr1-shRNA-AAV10; KD) virus. (C) Total number of bouts in each state. (D) shows 
the average length of each bout of waking, NREM, and REM. 
A 





HCRTr1 knockdown disrupts DA signaling  
To examine the extent to which HCRTr1 knockdown in VTA impacts DA signaling, rats 
received unilateral infusion of HCRTr1-shRNA-AAV10 (n=7) or SCRM-shRNA-AAV10 
(n=6). After 4 weeks of incubation, DA release and uptake were monitored in the NAc 
core using FSCV. As shown in Figure 7A, HCRTr1 knockdown significantly reduced 
stimulated DA release (t(10) = 5.15, p < 0.001) and reduced maximal uptake (t(10) = 
3.73, p = 0.0038) under baseline conditions relative to scramble controls (Figure 7B, 
7C). Importantly, however, when expressed as a percent of baseline, HCRTr1 
knockdown did not reduce DA release following cocaine delivery (Figure 7D). Mixed 
design, repeated measures ANOVA, with viral treatment as the between-subjects 
variable and time as the within-subjects variable revealed no effect of virus (F(1,10) = 
2.82, p = 0.124), but did indicate a significant effect of time (F(16,160) = 9.4, p < 0.001) 
and a virus x time interaction (F(16,160) = 3.96, p < 0.001). Planned comparisons did not 
reveal significant differences between groups following cocaine delivery, indicating 
that cocaine exerts proportionally similar effects on DA release in both scramble and 




Nevertheless, HCRTr1 knockdown significantly attenuated cocaine-induced inhibition 
of DA uptake (Km; Figure 7E). Mixed design ANOVA revealed no significant effect of 
virus (F(1,10) = 1.64, p = 0.23) but did indicate a significant effect of time (F(16,160) = 
29.97, p < 0.001), and virus x time interaction (F(16, 160) = 4.06, p < 0.001). Subsequent 
analysis indicated that HCRTr1 knockdown significantly reduced cocaine-induced DA 
uptake inhibition at the 1 min (t(10) = 2.23, p = 0.049) and 5 min (t(10) = 2.53, p = 0.03) 









Figure 7. HCRTr1 knockdown disrupts dopamine (DA) signaling under baseline (BL) 
conditions and in response to cocaine (A) Example traces of stimulated DA release 
prior to and following 1.5 mg/kg intravenous cocaine in rats treated with the scramble 
(SCRM-shRNA-AAV10; SCRM) or HCRTr1 knockdown (HCRTr1-shRNA-AAV10; KD) 
virus. Shown are the mean +/- standard error of the mean for (B) stimulated DA 
release and (C) DA uptake rate (Vmax) in the NAc under BL conditions prior to cocaine 
for SCRM and KD animals. Shown are the mean ± standard error of the mean for (D) 
stimulated DA release expressed as a percent of baseline and (E) cocaine-induced DA 
uptake inhibition (Km), across the experimental session for SCRM and KD animals. 
Dashed lines indicate time of 1.5 mg/kg i.v. cocaine injection. * p < 0.05, ** p < 0.01, *** 




HCRTr1 knockdown alters dopaminergic protein expression in the NAc 
 
To address the significant neurochemical effects observed in the voltammetry 
experiments, we investigated the extent to which HCRT KD affected the expression of 
key DA synthesis and transport proteins in the NAc. After transfecting animals with 
HCRTr1 knockdown or SCRM virus for a period of 4 weeks, we assessed the relative 
levels of DA transporter (DAT), Vesicular monoamine transporter (VMAT), and tyrosine 
hydroxylase (TH) proteins, with actin levels used as a control for overall level. We also 
assessed relative phosphorylation of TH at its serine 40 site. We found that overall 
levels of TH were not significantly different in HCRTr1 KD tissue compared with SCRM 
tissue (SCRM = 3.73 +/- 0.55 au), (HCRT = 4.15 +/- 0.81 au) (T (28) = 1.17, p > 0.1). 
Additionally, we found that phosphorylation of TH was unaffected at either its serine 
40 residue (SCRM =0.188 +/- 0.024 au) (HCRT =0.167 +/- 0.051 au), (T (28) = 0.33, p > 
0.1), or at its serine 31 residue (SCRM = 0.40 +/- 0.095 au) (HCRT = 0.33 +/- 0.08 au), 
(T (28) = 1.12, p > 0.1).  HCRTr1 KD tissue showed moderately higher DAT than SCRM 
tissue, though the difference was not found to be significant (SCRM = 4.34 +/- 1.42 
au) (HCRT = 6.37 +/- 2.11 au), (T (28) = 1.66, p > 0.05). Finally, VMAT expression was 
not significantly different between groups (SCRM = 1.34 +/- 0.13 au)  (HCRT = 1.22 






Figure 8. HCRTr1 knockdown does not alter the expression of selected proteins in the 
NAc tissue. Shown are the mean +/- SEM protein level (in A.u.) in NAc  tissue content 
of for levels of actin, tyrosine hydroxylase (TH), vesicular monoamine transporter 
(VMAT), dopamine transporter (DAT), TH phosphorylated at serine-31 (THser31), and 
TH phosphorylated at serine-40 (THser40), and  protein in NAc tissue of animals 
injected with HCRTr1-KD and SCRM, expressed in terms of fluorescent 







In the present studies, we used a viral shRNA approach to determine the degree of 
VTA HCRTr1 involvement in the regulation of cocaine self-administration and DA 
signaling in the NAc. We demonstrate that HCRTr1 knockdown disrupts acquisition of 
cocaine self-administration and reduces motivation for cocaine, without affecting 
sleep/wake activity. Further, HCRTr1 knockdown also disrupts DA release and uptake 
under baseline conditions and attenuates the effects of cocaine on DA uptake. These 
observations indicate that HCRTr1 influence the motivation for cocaine likely via 
actions on mesolimbic DA signaling. 
 
HCRTr1 knockdown alters the motivation for cocaine 
 
Numerous observations suggest that HCRTr1 influences motivated behavior, 
particularly as it relates to drugs of abuse. However, the majority of studies examining 
HCRT regulation of motivated behavior have employed systemic delivery of HCRT 
agents, and consequently the specific neural structures involved in these actions is 
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unclear. While limited observations suggests that the VTA may participate in HCRT-
mediated effects on behavior [27, 67], those observations relied on SB-334867, which 
has been criticized for potential off-target effects [194]. To address these potential 
limitations, we employed knock down of HCRTr1 specifically within the VTA and 
examined the effects on cocaine self-administration. Results indicate that HCRTr1 
knockdown delayed acquisition of cocaine self-administration without affecting 
cocaine intake on an FR1 schedule. Moreover, HCRTr1 knockdown also reduced the 
motivation for cocaine under a PR schedule. However, it must be noted that self-
administration was examined for only one dose of cocaine, which could influence the 
magnitude of HCRTr1 knockdown effects [228].  
 
Our experiments correlate well with previous studies which utilize acute manipulations. 
It has been well-established that acute reductions to HCRTr1 activity can have 
attenuating effects on high-effort schedules of responding such as PR, and these 
effects were now confirmed in a study utilizing long term HCRTr1 downregulation in 
VTA. However, previous studies have until now been unable to show a link between 
HCRTr1 and low-effort responding. We demonstrate that at the low-effort FR1 
schedule of reinforcement, acquisition is profoundly impaired. While this does not 
appear to be a function of preferred blood levels of cocaine (as the rate of 
consumption was still unchanged), such findings are highly notable. First, the effects 
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on both the FR and PR responding (combined with the lack of effect on sleep), denote 
that HCRTr1 within the VTA may be critical for both the establishment and 
maintenance of motivated behaviors. Finally, the effects on the acquisition of but not 
consumption of cocaine under low effort schedules suggests that HCRTr1 within the 
VTA may also be more important in guiding learning processes than previously 
supposed. 
 
HCRTr1 in the VTA are necessary for normal DA signaling 
Previous reports suggest that HCRT regulation of cocaine self-administration is likely 
mediated via actions on the mesolimbic DA system. For example, intra-VTA infusions 
of HCRT-1 peptide increase DA in the NAc [58], while HCRTr1 antagonists into the 
VTA decrease DA [67]. These observations are consistent with the present findings 
indicating that HCRTr1 knockdown in the VTA reduces DA release and uptake under 
baseline conditions and attenuates cocaine-induced DA uptake inhibition.  
 
While it is currently unclear whether the reduction in DA release predates the 
attenuation of DA uptake (or vice versa), it is likely that both effects are representative 
of an overall downregulation of DA signaling. Previous observations have indicated 
that a loss of HCRTr1 activity can reduce the excitability of cells which produce DA, an 
103 
 
effect which is likely to diminish the level of DA released into the synapse. This effect is 
indeed observed in the voltammetry experiments. In addition, long-term attenuation 
of synaptic DA levels also produce a reduction in DAT activity [239], leading to 
reduced baseline uptake of DA (another effect observed in the voltammetry 
experiments). Together, the reductions in both DA release and uptake constitute a 
fundamental change in the DA terminal, which substantially alter the DA response to 
cocaine (also an effect observed).    
 
Given the importance of NAc DA for supporting motivation for both cocaine [104] 
and natural [105] rewards, it is possible that the effects of HCRTr1 knockdown on 
baseline DA neurotransmission may have generalized effects on behavior. Indeed, 
previous observations indicate that HCRTr1 blockade reduces motivation for sucrose 
in sated but not food restricted rats [67] and affects self-administration of highly 
palatable foods but not regular chow [227]. However, previous work has 
demonstrated that HCRTr1 antagonism is effective at reducing food-maintained 
responding when the incentive level of motivation is low (in sated rats).  Importantly, 
these effects of HCRTr1 manipulations do not appear to be associated with 





We determine that long-term downregulation of VTA-HCRTr1 leads to a strong 
reduction in DA release. This may be a product of reduced excitability in the VTA, a 
reduced functionality of dopaminergic enzymes, or a combination of the above. The 
gradual reduction in synaptic DA levels may lead to compensatory effects in the 
presynaptic environment, such as reductions in the functionality or surface localization 
of the DAT, thereby slowing the rate of DA uptake, and diminishing the effects of 
cocaine (effects which were observed in the experiments). Whichever the precise 
mechanisms are, it is clear that HCRTr1 in VTA is essential for maintaining normal 
levels of DA neurotransmission.  
 
Effects on DA-associated proteins 
We also observed limited, nonsignificant alterations to the expression of proteins 
critical for dopaminergic signaling. Notably, the expression of TH, VMAT, and D2R 
were essentially unchanged. Such findings offer further evidence of targeted effects 
on HCRTr1. All of the former proteins are subject to regulation via ERK1/2 and PKC 
signaling, which are profoundly influenced by HCRTr1 [129, 214, 240], and it was 
possible that the reduction in HCRTr1 signaling could lead to changes in the activity of 
the dopamine machinery. However, as our viral vectors induce a roughly ~40% 
decrease in HCRTr1 mRNA, but no discernable effects on dopaminergic proteins, it is 
possible that HCRTr1 may be more responsible for the functioning of dopaminergic 
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proteins, rather than the quantity of their expression. Of particular note are the 
apparently paradoxical effects on the expression of DAT. After a period of 4 weeks, we 
observe reduced levels of DAT mRNA in the VTA, but increased levels of DAT protein 
expression in the downstream NAc (NAc). While neither one of these changes findings 
was statistically significant, both raise important questions about the function of the 
DAT, and highlight the transporter as a potential locus of HCRT-mediated effects on 
dopamine and behavior. Several studies have suggested that DAT expression in VTA 
may change during the course of drug addiction [241], and it is possible that 
interfering with this process, even slightly, could potentially induce strong alterations 
to the addictive phenotype. Further behavioral experiments will be needed to address 
this concern. 
 
The mechanisms through which HCRTr1 influences DA signaling are not well 
understood. One possibility is that knock down of HCRTr1 in the VTA disrupts DA 
release by reducing excitatory drive on DA neurons. Indeed there is substantial 
evidence to suggest that HCRT is responsible for mediating changes in DA neuron 
excitability, as HCRT-1 peptide exerts an excitatory influence on VTA DA neurons 
either directly [232], through suppression of GABAergic input onto DA neurons [242], 
and/or by enhancing glutamatergic drive onto DA neurons [26, 70]. These HCRT 
actions have been shown to increase DA neuron firing and bursting in vivo [23, 27], 
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which is known to increase DA at the terminal [109, 243]. Consistent with these 
observations, blockade of HCRTr1 reduces DA neuron firing, which is expected to 
reduce DA in target regions [27]. Based on these observations, it is reasonable to 
suggest that HCRTr1 knockdown results in a similar reduction in the excitability of DA 
neurons, which could diminish the effectiveness of electrical stimulation and result in 
reduced DA release as observed herein. Alternatively, HCRTr1 knockdown may exert 
its effects by differentially engaging distinct pools of releasable DA [106, 244] which 
may involve synapsin-dependent alterations to presynaptic Ca2+ influx [106, 245, 246].  
Extensive evidence suggests that DA signaling in the NAc is influenced by a number of 
second messenger signaling cascades that affect surface localization and functionality 
of the DAT [247, 248]. Thus, in addition to modulating DA neuron firing directly, 
HCRTr1 knockdown may also influence DA signaling via alterations to the DA 
terminals. For example, recent observations suggest that HCRT is capable of 
modulating signaling cascades such as protein kinase C and calmodulin-dependent 
protein kinase II, which affect the phosphorylation and glycosylation of DAT [21, 240], 
and may therefore influence DAT surface localization and functionality [117, 248]. 
Given that baseline DA uptake is dependent on functional DATs, modifications that 
alter DAT levels at the cell surface result in changes in baseline DA uptake rates, an 
effect that can alter psychostimulant potency [125]. Therefore, HCRT-induced changes 
in DAT function at the terminal may underlie the diminished effects of cocaine at 
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inhibiting DA uptake. We have previously demonstrated that animals treated with a 
HCRTr1 antagonist [67, 69, 162] display reduced cocaine-induced DA uptake 
inhibition, possibly due to alterations in DAT function. It is possible, therefore, that 
HCRTr1 knockdown may attenuate the effects of cocaine through such a mechanism. 
The presents findings offer some evidence for DAT-driven effects, given that HCRTr1 
knockdown had little effect on DA release following cocaine but nevertheless reduced 
cocaine-induced DA uptake inhibition. 
 
Conclusions  
We determined that sustained knockdown of HCRTr1 in the VTA alters both DA 
signaling in the NAc, and cocaine-reinforced behavior, without affecting arousal. 
These observations offer further evidence in support of the hypothesis that HCRTr1 in 










Chapter 5: Expanding HCRTr1 knockdown to a cell-specific 





The HCRTr1 exerts a powerful influence on mesolimbic dopaminergic signaling. We 
have previously demonstrated that viral knockdown of HCRTr1 in the VTA produces 
significant effects on dopamine neurotransmission and on motivated behavior. 
However, it remains unclear whether these effects are primarily mediated through 
alterations to dopaminergic cells, alterations to the firing of GABAergic cells, or a 
combination of both mechanisms. Further, it also remains unclear how HCRTr1 affects 
the pre- and post-synaptic environment in the mesolimbic circuit. In our final series of 
experiments, we utilized cell-specific knockdown of HCRTr1 in the VTA, to further 
investigate the role of HCRT in the functioning of both dopamine- producing cells in 
the region. We used qRT-PCR to determine the extent of viral knockdown (and the 
magnitude of the specific effects on the expression of dopaminergic proteins) and TH-
specific HCRTr1 knockdown. We determine that TH-specific viral knockdown led to a 
strong reduction in overall HCRTr1 expression, without producing significant effects 
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on the expression of other proteins. We also determined that TH-HCRTr1 KD 
produces nuanced effects on dopaminergic signaling. Using an ex-vivo FSCV 
preparation, we first determined that TH-HCRTr1 KD reduced dopamine release 
under low concentrations of cocaine, and blunts the effects of high doses of cocaine 
on the uptake of dopamine. We then utilized in-vivo extracellular electrophysiology to 
assess the effects of TH-HCRTr1 KD on the post-synaptic environment of the NAc 
core. We determined that TH-HCRTr1 KD slightly reduces the overall firing rate of 
medium spiny neurons (MSNs) in the NAc in vivo. We also determined that such 
knockdown increased the sensitivity of Type 1 (dopamine-excited) MSNs under the 
presence of cocaine, while having no major effect on Type-2 (dopamine-inhibited) 
MSNs. These experiments provide critical information about the role of HCRTr1 in 
dopaminergic neurotransmission, and provides an additional degree of detail in to the 




The hypocretin/orexin system exerts a powerful influence on the mesolimbic 
dopamine system. We have previously demonstrated that HCRT manipulations to the 
ventral tegmental area (VTA) profoundly affect dopamine release [67], and dopamine 
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uptake [249]. This may be due to direct actions on dopamine-producing cells. First, 
HCRTr1 are present at moderately high concentrations in the VTA [168], a region 
which is comprised of 55-65% DA cells [250]. Second, HCRTr1 is critical for 
maintaining the excitability of dopaminergic cells, as manipulations to HCRTr1 activity 
can cause significant changes to firing rates of putative DA cells [81]. Third, changes in 




While it is clear that HCRTr1 can modulate some degree of the cellular activity of the 
VTA, the precise actions remain mostly unexplored. First, HCRTr1 are found on both 
dopaminergic and GABAergic cells in the VTA [163], [213]), and it is unclear whether 
manipulations to HCRTr1 signaling in the VTA alter dopamine release through actions 
on one or both cell types, or a combination of both. Furthermore, it is unclear how 
long-term modulation of HCRTr1 can affect dopamine signaling in downstream 
regions, and what effects this may cause on the local environment.  
 
This is a particularly important issue with the NAc. The NAc is a crucial region for 
controlling motivated behavior, and receives a greater percentage of dopaminergic 
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input than any other region of the brain [251]. Acutely reinforcing events are often 
marked within the brain by a significant release of DA into the NAc [116], and this 
release of DA into the NAc is considered one of the strongest factors that influence 
behavior [252]. Such influxes of DA can profoundly alter the firing of medium spiny 
neurons (MSNs) [149], cells which are crucial for the establishment and maintenance 
of motivated behavior [176]. The effects of DA in the NAc are largely dependent on 
the cell types receiving the input. ~95% of the cells in the NAc are MSNs [253], which 
are either excited by dopamine via D1 receptors (Type 1), or inhibited by DA via D2 
(Type 2) [254]. Both types of MSNs are critical for shaping motivated behavior, and 
show changes in activity during cocaine self-administration [255, 256]. 
 
In order to determine how HCRT specifically affects dopaminergic cells in the VTA, we 
modified our method of viral knockdown to specifically target HCRTr1 in cells which 
express tyrosine hydroxylase, the rate-limiting enzyme in dopamine production. We 
utilize a combinatorial viral approach, in which one virus induces CRE expression in 
the neurons of interest, and a mixture of multiple CRE-specific HCRTr1 knockdown 
viruses combine to interfere with HCRTr1 mRNA expression in only the cells which 
have incorporated the CRE recombinase into their genome. This approach enables 
selective targeting of specific cell types, continues to minimize toxic effects through 
use of nonpathogenic vectors,  and allows for the use of wild-type, genetically 
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unmodified animals. We applied TH-specific viral knockdown, and assessed the effects 
on the expression of dopamine-specific proteins using qRT-PCR. We then assessed 
the effects of TH-specific HCRTr1 KD on the stimulated dopamine release and uptake 
under different doses of cocaine, utilizing an ex-vivo slice voltammetry preparation. 
Finally, we assessed the effects of TH-specific HCRTr1 KD on the firing rate of medium 
spiny neurons in the NAc, using in-vivo extracellular electrophysiology.  
 




Adult (350-400 g), male Sprague-Dawley rats (Harlan Laboratories, Frederick MD) 
were housed on a reverse light/dark cycle and given ad-libitum access to food and 
water. Animals were pair-housed prior to receiving infusions of viral vectors and 
subsequently single-housed. All protocols and animal procedures were conducted in 
accordance with the National Institutes of Health (NIH) Guide for the Care and Use of 
Laboratory Animals under the supervision of the Institutional Animal Care and Use 




Microwire arrays  
 
Arrays for the electrophysiology experiments were assembled by hand. Using a 
weighted spring, the arrays were configured in two rows of four microelectrodes, with 
500 μm of space between rows and 200 μm of space between electrodes within a 
row. Microelectrodes consisted of 50 μm insulated stainless steel wire with exposed 
tips connected to a 10-pin omnetics connector. Recording electrodes were soldered 
onto channels 1-8 of the 10-pin connector, with channels 9 and 10 serving as the 
reference and soldered together. Layers of epoxy were applied over the connections 
to insulate them, and the wires were run through a piece of shrink tubing. The entire 
assembly was fixed in place with epoxy, and the wires were then pulled taught and 
centered with a spring, positioned roughly 3 inches from the end of the shrink tubing. 
Melted polyethylene glycol (PEG) was applied over the taut wires, for 3 centimeters 
below the end of the shrink tubing. Once the PEG had solidified, the wires were cut, 
so that only 500-800um of wire was present below the end of the PEG covering. The 
connector piece was attached to a connector plug on the opposing side, for 
connection to the recording preamplifier [257, 258]. Arrays were kept at RT and away 




Preparation of viral vectors 
 
We utilized shRNA viruses, which have been shown to modulate the expression of 
target proteins [259]. Vectors were created at the University of Buffalo, under the 
direction of Dr. Caroline E. Bass. To induce cellular-specific effects, we utilized a 
cocktail of multiple viruses. To target dopaminergic cells, we used a TH-iCRE virus 
recently developed in the lab of Dr. Bass. The TH-iCRE virus comprised of a 2.5Kb 
sequence of the rat TH promotor gene [260], cloned into an pAAV vector, with an 
optimized CRE recombinase gene inserted into the vector, downstream (3’) from the 
promotor region. This virus has been shown to reliably induce CRE expression in TH-
containing cells [211]. This virus was then combined with a combination of SICO-
HCRTr1-shRNA-AAV10 viruses, which produce shRNAs in cells which express CRE 
recombinase. This is a novel approach, where a second virus either turns the CRE 
gene on or off [261]. One similarity to the generic approach, is that the SICO-HCRTr1 
viruses were delivered as a mixture of viruses, which each targeted a slightly different 
sequence on the HCRTr1 gene (either TGGTGCGGAACTGGAAGCGA, 
TGGCGCGATTATCTCTATCCG, or TAGCCAATCGCACACGGCTCT). This approach was 
performed due to previous evidence which suggested that combinatorial approach 
can produce a stronger cumulative effect, compared with a single virus [198]. Similar 
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to the generic viruses, the SICO-HCRTr1 viruses consisted of 20 - 21 nucleotide target 
sequences, a loop sequence (ACTCGAGA) containing an XhoI site, and the antisense 
to the HCRTr1 target sequence, which was the same in all variants of the virus. In the 
CRE-dependent scramble control virus, the shRNA does not target any known RNA 
sequence in the rat genome. 
 
Virus infusion  
 
To deliver the viral vectors, animals were anesthetized with isoflurane and placed into 
a stereotaxic frame, with the skull flat. To target VTA, a 1 mm hole was drilled in the 
skull (−5.25 mm A/P, +0.95 mm M/L relative to bregma) and a glass injection pipette 
(Sigma Aldrich, St. Louis MO) was lowered into the VTA, reaching a final depth of 7.8 
mm ventral to the brain surface. Glass pipettes were cut to an inner diameter of ~30 
µM. After waiting 10 min to allow tissue to settle, 0.5 µl of the viral combinations were 
delivered into each hemisphere of the VTA over 10 min using a picospritzer. For qRT-
PCR and ex-vivo voltammetry experiments, both hemispheres of VTA were infused 
with the same virus combination. For the in-vivo electrophysiology experiments, virus 
was infused only into the right hemisphere of VTA. The central region in which the 
viruses were injected previously been shown to express moderate levels of HCRTr1 
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[159, 262]. Following surgery, animals were housed singly, administered ketoprofen (5 
mg/kg, s.c.) at 12 hr intervals for 36 hr, and then designated for molecular, behavioral, 
or neurochemical experiments.  
 
Quantitative reverse transcriptase PCR (qRT-PCR)  
 
Rats received infusion of TH-specific HCRTr1 knockdown cocktail, or scramble virus 
cocktail into both hemispheres of VTA. After 4 weeks of incubation, animals were 
anesthetized with isoflurane and rapidly decapitated. Brains were extracted over ice 
and placed into a matrix slicing guide on ice, with the ventral surface visible. Two 
coronal cuts were made, with the rostral cut at the caudal portion of the mammillary 
bodies, and the second cut made 2.0 mm caudal to the first, yielding a single slice 
(−4.4 to −6.4 mm A/P relative to bregma) encompassing the majority of VTA. The 
tissue comprising VTA was taken as the area ventrolateral to the periaqueductal grey, 
ventral to the mesencephalic reticular nucleus, and medial to the substantia nigra. In 
all cases, each animal received the same viral combination in both hemispheres, in 
order to prevent cross-contamination of viral effects, and to account for the potential 
of imprecise infusions.  Immediately following extraction, tissue was placed into 75 µl 
of RNAlater (Qiagen Inc., Valenia, CA, USA), and stored at −20° C until processing. 
Total RNA was purified as previously described [206], with resulting A260/A280 ratios 
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between 2.01 and 2.18, indicating high purity. cDNA was reverse transcribed and qRT-
PCR was conducted as described previously [206], using a StepOnePlus Real-Time 
PCR System (Applied Biosystems, Grand Island, NY). Expression of HCRTr1, HCRTr2, 
tyrosine hydroxylase (TH), vesicular monoamine transporter (VMAT), D2 DA receptor 
(D2R) and the DA transporter (DAT) were quantified relative to cyclophilin-A using the 
relative quantification method (ΔΔCT). Primers were designed with the NCBI Primer 
design tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/; [207], and obtained 





Treatment animals (TH-KD) were infused intra-VTA with the combination Th-iCRE 
virus, and a combination of the 3 cre-dependant HCRT knockdown viruses. Control 
animals (TH-SCRM). Control animals were given the Th-CRE virus, combined with a 
cre-dependant scramble virus, which only encoded for a green fluorescent (GFP) 
product. After 2 weeks of incubation, animals were anesthetized with isoflurane and 
rapidly decapitated. Brains were rapidly removed following decapitation and were 
transferred to oxygenated, ice-cold artificial cerebral spinal fluid (aCSF) containing (in 
mM) NaCl (126), KCl (2.5), NaH2PO4 (1.2), CaCl2 (2.4), MgCl2 (1.2), NaHCO3 (25), 
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glucose (11), and l-ascorbic acid (0.4), as well as pH adjusted to 7.4. A vibrating 
microtome was used to produce 400-μm- thick sections containing the NAc. Slices 
were allowed to rest at room temperature for 1 h before being transferred into a 
testing chamber flushed with aCSF (32 °C). A bipolar stimulating electrode (Plastics 
One) was placed on the surface of the tissue and a carbon fiber microelectrode was 
implanted in the NAc between stimulating electrode leads. DA release was evoked 
every 3 min using a single electrical pulse (400 μA, 4 ms, monophasic). After recording 
three stable baseline responses (three stimulations with <10% variation), cocaine was 
cumulatively applied to the tissue (0.3–30 μM) as previously described [162, 228, 238]. 
Stimulated DA release and DA uptake measures (Vmax and Km) were determined via 
Michaelis Menten kinetics, as previously described [162].  Differences in baseline DA 
release and uptake were assessed using independent samples t tests, and differences 
in the effects of cocaine were assessed using a two-way ANOVA with viral treatment 
as the between-subject variable and cocaine concentration as the repeated measures 
variable. 
 




Animals were infused intra-VTA with either the TH-KD or TH-SCRM combinations. In 
all cases, the virus was delivered unilaterally. Animals were given 2 weeks to recover, 
and then anesthetized with 2% isoflurane. Animals were implanted with an acute 24g 
catheter into the left jugular vein, and placed into a stereotaxic frame. The scalp was 
opened up to expose the skull. A large hole (2.5mm diameter) was drilled above the 
NAc; the dura mater was cleared, and the assembled microwire bundles were slowly 
lowered to a depth of 6.3-6.7mm ventral to brain surface. Electrodes were lowered 
slowly; at a rate of 100-150um per minute, as saline was applied to dissolve the PEG 
casing. Signals were recorded using Plexon Sortclient [257], using gain settings 
between 2x-10x, which have been previously determined to record MSN firing rates 
[257]. The mean firing rate of MSNs are widely believed to be between 2-8 Hz with 
lateral inhibition, and 15-25 Hz without lateral inhibition, which can occur during 
periods of bursting from afferent regions [263]. Upon reaching a site of stable firing at 
the coordinates of the NAc core, baseline cellular activity was recorded for 30 
minutes. Immediately following baseline recordings, animals were injected with 1.5 
mg/kg cocaine IV through the implanted catheters. Cellular firing was then recorded 
for a further 60 minutes, in accordance with previously published methods [264]. 
Single-unit activity was recorded using the MAP system (Plexon Inc, TX, USA) using 
established procedures [257]. Subsequent to recording, units were further sorted and 
isolated via Offline Sorter (Plexon Inc, TX, USA), using previously published methods. 
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Briefly, neurons with a spike period of less than 50ms were chosen. Spikes were 
defined as a peak-valley difference of at least 60mV. Cells were considered MSNs if 
they demonstrated a reliable firing signature throughout the duration of the 
experiment. Following all recording and further sorting, spike data from sorted units 
was processed using Neuroexplorer 4 (Nex Technologies). Units which demonstrated 
a stable baseline firing rate (defined as an average rate of firing over 30 consecutive 
1-minute intervals in which each 1-minute bin did not deviate from the previous bin 
by more than 20%), and where post-cocaine firing persisted for a minimum of 30 
minutes following injection, were selected for analysis. We considered units which met 
MSN firing rate criteria, and expressed an increased or unchanged frequency 
following cocaine, as Type 1 cells, which thus may represent D1 receptor containing 
MSNs [265]. By comparison, Type 2 MSNs reduced their frequency in the presence of 
cocaine and thus may represent D2 receptor containing MSNs[266]. Proportion of 
MSNs, and initial firing rates were compared via unpaired t-tests, along with the 
overall effect of treatment on cocaine induced firing.  
 




At the conclusion of electrophysiology experiments, rats were anesthetized with 5% 
isoflurane until cessation of breathing. Animals were then transcardially perfused (with 
all fluids delivered to the left ventricle, and exiting out of the cut right atrium) and 
transcardially perfused with 140 ml saline, followed by 150 ml of 10% formalin in 0.01 
M phosphate-buffered saline (pH 7.4). Saline was delivered at an initial rate of 20ml 
per minute, and formalin was delivered at a rate of 15ml/min for the first 5 minutes, 
and 10ml/min thereafter. The skull and dura were carefully removed, and brains were 
placed in a 10% solution of formalin in PBS for an additional 60 minutes at room 
temperature. After 1 hour had elapsed, brains were then transferred to a solution of 





Paired student’s t-tests were used to measure effects of TH-SICO HCRT and TH-SCRM 
on mRNA expression of HCRTr1. Further, independent student’s t-tests were 
conducted to measure differences in mRNA expression of DAT, D2R, HCRTr2, VMAT, 
and TH between the TH-HCRTr1 KD and the TH-SCRM viral treatment. Student’s t-
tests were also used to measure differences in baseline DA release and DA uptake 
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(Vmax) prior to cocaine in FSCV experiments. Stimulated DA release, and cocaine-
induced DA uptake inhibition (Km) across the doses of cocaine of the experiment were 
assessed using a two-way ANOVA, with viral treatment serving as the between-
subjects variable and cocaine dose as the within-subjects variable. In the 
electrophysiology experiments, cells whose firing persisted throughout the duration of 
the experiments were sorted for further processing. Initially, independent samples t-
tests were used to compare the baseline firing rate of all sorted and processed MSNs. 
The average frequency of units in the last 5 minutes of baseline, compared with the 
first 5 minutes following cocaine, was used to assign the cells to either Type 1 
(increased following cocaine) or Type 2 (decreased following cocaine). Average 
frequency was recorded in 5-minute bins, for the last 15 minutes of baseline and the 









To assess the effectiveness of viral transfection, rats were bilaterally injected intra-VTA 
with the TH-iCRE virus and either the TH-dependent HCRTr1 knockdown viral cocktail 
(TH-KD), or the CRE-dependant scramble control (SCRM). The TH-KD combination led 
to a nearly 30% reduction in HCRTr1 mRNA, compared with SCRM (t(28) = 2.954.5, p < 
0.005). Further, TH-KD did not produce a significant effect on the expression of 
HCRTr2 (t(22) = 0.21, p > 0.1), DAT (t(22) = 0.562, p > 0.1), D2R(t(22) = 0.26, p > 0.1), TH 
















Figure 9. TH-HCRTr1-KD reduces HCRTr1 expression in the ventral tegmental area. 
Shown are the mean ± standard error of the mean (SEM) of mRNA levels for HCRTr1, 
hypocretin receptor 2 (HCRTr2), tyrosine hydroxylase (TH), vesicular monoamine 
transporter (VMAT), D2 DAr (D2R), and dopamine transporter (DAT) in the VTA 
following injection of the scramble (TH-SCRM; SCRM) or TH-HCRTr1 knockdown (TH-
HCRTr1-KD; KD) viruses.   ** p < 0.005. 
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Effects on DA release and uptake ex-vivo 
Rats were injected unilaterally with TH-KD or TH-SCRM. We determined that 
electrically stimulated DA release was not significantly different between groups under 
baseline conditions (t(9) = 0.82, p > 0.1 (Figure 10A). Additionally, we observed slight 
differences in stimulated release between TH-KD and TH-SCRM- injected animals 
under different doses of cocaine. Baseline DA release was not statistically significant 
between groups (p > 0.1). At the lowest dose of 0.3uM, we found a significant 
reduction in dopamine release in TH-HCRT treated animals (t(9) = 2.77, p = 0.011). 
However, we observed no major effects at any higher dose. 1um (t (9) = 0.457, p > 
0.1), 3um (t (9) = 0.195, p > 0.1), 10um (t (9) = 0.416, p > 0.1), and 30uM (t (9) = 
0.192, p > 0.1) (Figure 10B). VMAX levels were not found to be significantly different 
between the two groups (t(9) = 1.11, p > 0.1) (Figure 10C). The effects of cocaine on 
uptake inhibition were mixed, with TH-specific HCRTr1 knockdown causing blunted 
effects of cocaine at the high dose 30um(t(9) = 2.41, p = 0.019), but with no effect on 
lower doses; 0.3um (t(9) = 1.27, p > 0.1),  1um (t(9) = 0.356, p > 0.1), 3um(t(9) = 
0.288, p > 0.1), 10um(t(9) = 0.997, p > 0.1). (Figure 10D). Additionally, two-way mixed 
design ANOVA with viral treatment serving as the between-subject variable and 
cocaine concentration as a repeated measures variable revealed a significant effect of 






Figure 10. TH-KD produces varied effects on DA neurotransmission, under baseline 
conditions and in response to cocaine. Shown are the mean ± standard error of the 
mean for (A) Baseline level of stimulated DA release in the NAc. (B) Stimulated DA 
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release in the presence of 0.03, 0.1, 0.3, 1, and 3 mM of cocaine HCl. (C) DA uptake 
rate (Vmax) in the NAc under BL conditions prior to cocaine for SCRM and KD animals, 
(D) Cocaine-induced DA uptake inhibition (Km), across the different experimental 

















Effects on postsynaptic activity 
 
We observed that TH-KD induced several significant differences to the firing patterns 
of MSNs in the NAc. First, we evaluated the pattern of GFP expression in VTA and the 
location of the recording electrodes in the NAc. Animals’ data were included in 
analysis only if the placement of electrodes were found to be substantially in NAc core 
(Figure 11A).The firing rate of all units was measured across the entire duration of 
time, but baseline and cocaine-induced firing rates were taken as the average of the 5 
minutes before, and the 15 minutes after cocaine injection, respectively (Figure 11B, 
11C). .  Across all 7 animals in the SCRM condition, we recorded 24 cells which met 
criteria for MSN firing and persisted throughout the experiment (Average frequency: 
11.7 +/- 0.97 Hz) (Figure 12A). In the TH-KD condition, we recorded 28 cells from 7 
animals (Average frequency: 10.3 +/- 1.2 hz) (Figure 12A). The overall frequency of 
MSNs was found to be lower in TH-HCRTr1 KD treated rats, compared with SCRM 
controls (t(48) = 2.12, p = 0.049). Additionally, we observed a difference in the nature 
of the MSNs recorded. In SCRM-treated animals, the firing rate of 4 of 24 cells either 
increased or remained the same following cocaine infusion, while 20 of 24 showed a 
decreased firing rate following cocaine (Figure 12B). Conversely, in TH-KD treated 
animals, the firing rate of 10 of 28 cells either increased or remained the same 
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following cocaine infusion, while 18 of 28 showed a decreased firing rate following 
cocaine (Figure 12B).. We observed no significant difference in the specific baseline 
firing rate of either Type 1 cells (SCRM = 8.2 +/- 2.2 hz; TH = 6.5 +/- 1.7 hz, t(12) = 
0.92, p > 0.1) (Figure 12C) or of Type 2 cells (SCRM = 11.9 +/- 2.2 hz; TH = 11.2 +/- 
1.1 hz, t(26) = 1.25, p > 0.1) (Figure 12E). Upon administration of cocaine, we observed 
a significant effect of cocaine on the firing rate of Type 1 cells on both TH-KD treated 
animals (p = 0.017), but no significant effects in SCRM-treated  animals (p > 0.1) 
(Figure 12D). Conversely, we observed a significant effect of cocaine on the firing rate 














Figure 11. Electrophysiological recording. (A) Representative photomicrographs, at 
40x and 100x magnification, depicting nissl staining of cells within the NAc. Red circles 
indicate terminal location of microwire electrodes. Scale bar is 0.25 mm. (B) Sample 
trace of a Type 1 MSN pattern of firing, in the 5 minutes before and 10 minutes 
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following injection of 1.5mg/kg i.v. cocaine. (C) Sample trace of a Type 2 MSN pattern 







Figure 12. Characterization of postsynaptic effects. Shown are the (A) mean +/- SEM 
of the firing rate for all recorded MSNs under SCRM (N=24) and KD (N=28) 
conditions. (B). Percentage of Type 1 and Type 2 cells recorded in TH-SCRM and TH-
KD animals. (C) Mean +/- SEM of the baseline firing baseline firing rate for recorded 
cells whose firing rate increased or remained unchanged following cocaine infusion 
(Type 1). (D) Percent change in firing rate in Type 1 cells following injection of 1.5 
mg/kg i.v. cocaine, in SCRM and KD treated animals. (E) Mean +/- SEM of the 
baseline firing baseline firing rate for recorded cells whose firing rate decreased 
following cocaine infusion (Type 2) . (F) Percent change in firing rate in Type 2 cells 
following injection of 1.5 mg/kg i.v. cocaine, in SCRM and KD treated animals.* p < 













In these studies, we assess the molecular, neurochemical, and postsynaptic effect of 
TH-specific knockdown of HCRTr1 in the VTA. We determine that TH-specific 
knockdown led to a decrease in overall HCRTr1 that was proportionally similar to that 
observed with generic HCRTr1 knockdown (Bernstein et al 2017). In addition, TH-
specific knockdown also produced a similarly benign effect on the expression of 
dopaminergic proteins, lending further weight to the hypothesis that HCRTr1 effects 
are not primarily due to changes in DA machinery. However, while TH-specific viral 
knockdown did induce similar effects on mRNA expression, the overall effects on 
dopaminergic signaling were somewhat more nuanced with the cell-specific 
approach. First, the initial state of the dopamine terminal does not appear to be 
altered under baseline conditions, as both SCRM and KD groups demonstrated similar 
levels of dopamine release and dopamine uptake. This in itself is not entirely 
unsurprising. HCRTr1 are located mostly on the soma and dendrites [159], and it is 
possible that a reduction in HCRTr1 density may have little effect on the excitability of 
the DA terminal, where excitability is primarily mediated through other mechanisms 
such as D1/D2 receptor activity [267]. Hence, it is possible that HCRTr1 knockdown 
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alters the excitability of the DA cell bodies and dendrites, but not of the axon or 
terminals, a finding which would be largely consistent with the larger effects observed 
with VTA stimulation, compared with NAc stimulation. 
 
Such differences may also account for the subtle discrepancies observed in the 
electrophysiology experiments. While the D2-mediated response to cocaine was 
largely consistent between treatment and control groups, we observed stronger 
effects on D1-mediated responses in TH-KD animals. Type 1 MSNs represented both 
a higher proportion of overall cells recorded (though still within established limits[268]. 
Further, Type 1 MSNs also demonstrated a larger proportional response to cocaine 
activation in the animals with TH-specific knockdown. Such results raise important 
questions about the effects of viral knockdown in VTA on efferent regions. HCRTr1 is 
important for the regulation of G protein-mediated excitability, and cells which lose 
this type of excitability, directly or indirectly (due to changes in DA input) may respond 
by changing the pattern of DAr expression downstream. This effect has been 
previously observed in animals with a loss of Gα [269]. Hence, it is possible that 
HCRTr1 KD reduces the excitability of dopaminergic cells, leading to lower dopamine 
signaling. In order to compensate for such changes, cells which receive strong DA 
input have demonstrated a corresponding increase in D1 expression [270], and a 
potential downregulation of D2 [268], following DA reduction. Under these 
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circumstances, a 1.5mg/kg dose of cocaine has been shown to increase DA in the 
synapse [80, 234]. This would be expected to reduce the firing rate of Type 2 MSNs 
[271]. However, there would also be an increase in the firing rate of Type 1 MSNs, 
which are excited by the cocaine-induced influx of dopamine [272]. In addition, the 
effects of HCRTr1 KD over the preceding weeks could potentially reduce the overall 
level of DA input to the striatum, as HCRTr1 antagonism has been shown to reduce 
the excitability of cells [26], which lowers cellular firing [81], and leads to lower DA 
release [27]. Consequently, cells which are normally excited by dopamine (Type 1), 
would likely have to increase their sensitivity to dopamine in order to maintain 
previous levels of activity, a finding which has been shown to occur during periods of 
DA downregulation, such as during drug withdrawal [273]. This appears to be exactly 
what happened in the NAc, as a greater proportion of the cells appear to contain D1, 
and also demonstrate a greater degree of sensitivity to rises in synaptic DA levels. In 
addition, such changes could be expected to initially favor D1 (Type 1) cells, for two 
reasons. First, D2 are considered to be more resistant to short-term changes in DA 
signaling, compared with D1 [274, 275]. Second, D2 receptors are located on both 





Changes to the relative pattern of MSN firing can produce strong changes to the 
physiology of the NAc, which have been shown to alter motivated behaviors. It has 
been previously shown that even small changes in DA levels can alter the structure 
and functioning of the NAc, and this can have profound impacts on motivated 
behavior in people [276]. Upon reducing HCRTr1 expression in the DA cells of the 
VTA, the rates of dopamine release and uptake are substantially altered, and the 
response to cocaine is also altered, denoting a probable change to the underlying cell 
physiology. This remains a plausible explanation, given that dopaminergic cells which 
demonstrate an altered rate of DA uptake often also display differences in excitability 
[171]. As HCRTr1 has been previously shown to be a strong regulator of cellular 
excitability [81], especially in dopaminergic cells [26], this presents a potential 
mechanism by which HCRTr1 may interact with the dopamine circuit.  
 
While further research will be needed to fully confirm these initial, DA-specific effects, 
we are highly confident that HCRTr1 may affect behavior, at least in part, through 
modulation of the excitability of dopaminergic cells. When HCRTr1 function is 
impaired, dopamine-producing cells reduced their level of excitability, and reduce 
their firing rate [81], which will alter the physiology of downstream cells which derive a 
substantial portion of input from DA receptor binding. HCRT-driven effects on DA cell 
excitability have been previously established in the literature [26], and are associated 
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with lower dopamine release and slower dopamine uptake [249]. Such effects are 
likely to produce significant alterations to regions which receive a high level of DA 
input, such as the NAc [277] and prefrontal cortex [278], where a high degree of 
cellular activity is driven by DAr binding. The attenuation in DA neurotransmission, 
induced by the reduction in HCRTr1 activity, leads to reduced modulatory input to 
medium spiny neurons, which has been shown to be associated with weaker 
behavioral associations [279], and a consequently blunted psychotropic effect of 
substances of abuse, particularly substances which directly modulate dopaminergic 
signaling, such as cocaine [280].  
 
Hypocretin research has been steadily expanding over the previous decade, and 
many public and private institutions have devoted significant resources towards 
evaluating the HCRT system as a potential therapeutic target for pharmacological 
interventions [40]. Consequently, the current research will be critical to guiding future 
inquiries into the potential efficacy of treatments which target the HCRT system, 
particularly if the treatment is to cover an extended period of time. Compounds which 
target the HCRT system, particularly dual HCRTr antagonists, have been evaluated as 
potential treatments for many behavioral conditions, such as narcolepsy, substance 
abuse, and obesity [40]. In many clinical trials, such treatments have been delivered 
chronically, over an extended period of time [40]. Hence, it is critical to assess the 
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long-term effects of HCRTr1 modulation, and evaluate for potential side effects and 
tolerance. Taken together, cell-specific knockdown of hypocretin receptors in the VTA 
represents an important step in determining the mechanisms through which the HCRT 
system influences behavior and neuronal function, and lays important groundwork for 



















The current investigations have revealed much about the nature of hypocretin 
signaling, and its ongoing role in the brain. We have characterized the long-term, 
neuromodulatory role of the hypocretin 1 receptor in the VTA (see Figure 13 for 
model), by utilizing a series of viral vectors to manipulate its expression in a region- 
and cell-specific manner. These tools have allowed us to monitor effects on protein 
and mRNA expression, dopamine release and uptake, motivated behavior, and the 
firing rate of downstream neurons. Perhaps most importantly, we develop a new 
technique for inducing long-term downregulation of a specific protein without using 












HCRTr1 mRNA ↓↓↓ ↓↓↓ 
HCRTr2 mRNA No effect No effect 
DA protein mRNA No effect No effect 
Cell count No effect No effect 
Coc SA Acquisition  ↓↓ Not tested 
Coc Consumption No effect Not tested 
Coc SA Motivation ↓↓ Not tested 
Arousal No effect Not tested 
Baseline DA release ↓↓↓ No effect* 
Baseline DA uptake ↓↓ No effect* 
Coc uptake inhib ↓↓ ↓↓↓* 
DA protein level No effect Not tested 
BL Type 1 Not tested No effect 
Cocaine Type 1 Not tested ↑ 
BL Type 2 Not tested No effect 





Table 3. Summary of effects of HCRTr1 KD.  Shown in the table are the molecular, 
behavioral, and neurochemical effects of HCRTr1 knockdown, compared with the 
effects of the scramble control. The results of nonspecific KD are compared with those 
from the generic SCRM control virus; the results of TH-specific KD are shown relative 
to the effects of TH-specific SCRM control virus. Abbreviations: mRNA = messenger 
RNA level, measured in VTA. Coc SA = cocaine self administration. DA protein level = 
tissue level of DA proteins, measured in NAc. BL = baseline firing rate of medium 
spiny neurons (Type 1 or Type 2), recorded in NAc; NAc = nucleus accumbens; VTA = 
Ventral tegmental area.  ↓ = p < 0.05;  ↓↓ = p < 0.01; ↓↓↓ = p < 0.005. *: With 
nonspecific HCRTr1 KD, DA release, uptake, and uptake inhibition were recorded in-
vivo, utilizing VTA stimulation, while with TH-specific KD, these measures were 










Behavioral role of HCRTr1 in the VTA 
 
Previous studies have implicated the VTA as a site of action for the hypocretin system, 
particularly as it relates to behavior. It has been shown that alteration of HCRTr1 
activity in this region can affect motivated behaviors, such as cocaine self-
administration. In many cases, local modulation of HCRTr1 activity in the VTA 
produces similar behavioral effects as systemic alterations to HCRTr1 signaling, 
denoting the importance of the VTA in mediating the effects of HCRTr1 [77]. Critically, 
these region-specific effects go in both directions, with increases in HCRTr1 activation 
leading to greater behavioral motivation, and HCRTr1 blockade reducing this measure 
[77, 80, 162, 228]. Because the region is so highly sensitive to changes in HCRTr1 
activity, we hypothesized that endogenous levels of HCRTr1 activity may be necessary 
for maintaining a baseline level of motivation, and may also be pertinent to the 
establishment of motivated behaviors from the onset. In order to test these questions 
accurately, it was imperative to utilize a technique that induced prolonged 
downregulation of HCRTr1, but also allowed a certain degree of endogenous 
signaling to persist. That is, we wanted to compare the effects of normal HCRTr1 
signaling with reduced HCRTr1, rather than completely ablated HCRT signaling. This 
has the advantage of maintaining a reduced (but consistent) level of HCRTr1 
throughout the multiple phases of our behavioral experiments, which would be more 
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readily comparable to studies utilizing acute manipulations, and likely allow the 
assessed behavior to continue to measurable extent. When we applied shRNA-
mediated knockdown, we determined that endogenous HCRTr1 was responsible for 
both the acquisition and maintenance of cocaine self-administration, a finding which 
had been hinted at in the literature, but had never been demonstrated in the same 
study before. Importantly, we also ascertained that these effects were not a by-
product of any significant changes to arousal. 
Such effects are likely to carry over into other forms of motivated behavior. We have 
shown previously that HCRTr1 antagonism with SB-334867 reduces high-effort 
responding for food based rewards in sated rats. This is consistent with our current 
findings, where HCRTr1 KD alters high-effort tasks like PR responding but not low-
effort behaviors like cocaine consumption on the FR schedule. Further, as our 
knockdown produced a slightly greater magnitude of effect on cocaine SA, compared 
with what has been published with acute HCRTr1 manipulations, we expect an 
accordingly strong effect on other reinforcers. HCRTr1 has been shown to alter 
alcohol preference, morphine preference, nicotine self-administration, and food-
based responding, and such measures are likely affected by an even greater decrease 
in localized HCRTr1 activity, which would be achieved with viral knockdown. 
 
Effects outside of the VTA 
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The effects of HCRT receptor knockdown may extend beyond operant reward 
seeking, particularly if HCRTr1 knockdown were to be investigated outside of VTA. 
HCRTr1 is located on many nuclei in the brain, where it plays a role in modulating 
excitability. This is particularly true in midbrain and brainstem nuclei with a 
preponderance of monoamine production. The locus coeruleus and dorsal raphe, 
(sites of norepinephrine and serotonin production, respectively), are particularly 
sensitive to HCRTr1 manipulations. For instance, HCRT-1 infusion into the LC has been 
shown to increase wakefulness [281], and blocking HCRTr1 within the region 
profoundly reduces REM sleep [282]. Hence, we would expect prolonged 
downregulation of HCRTr1 within LC to profoundly affect arousal. HCRT is one of the 
major mediators of cellular excitability within the region [42], and it has been shown 
that that the firing rate of cells in the LC are sensitive to changes in HCRTr1 activity 
[283].  As such, it would be interesting to evaluate HCRTr1 knockdown within LC 
would affect cellular firing rates as well as sleep/wake architecture; if both measures 
were indeed altered, it would bolster the case for HCRTr1 influencing behavior 
through direct modulation of the firing rate of monoaminergic neurons. In the dorsal 
raphe, which is critical for learning, and for modulation of emotional states, a 
reduction of HCRTr1 could be highly disruptive. HCRTr1 appears critical for the fos 
activation of neurons in the DR [284], and a loss of such excitation may similarly 
reduce serotonin production (as it does with dopamine in the VTA), and enhance 
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depressive-like states. This is a highly plausible possibility, as HCRT has been 
previously shown to be strongly implicated in depression [38, 285]. Furthermore, with 
the region functioning at a lower level, there may be potential deficits in learning [286, 
287]. Such effects might be particularly pronounced in behavioral tests which involve 
exposure to novel stimuli, such as the attention set-shifting task, or the 5-choice serial 
reaction task.  
 
Effects on dopamine 
 
HCRTr1 is also a potent regulator of dopaminergic signaling. Previously, we have 
demonstrated that dopamine release and uptake can be impacted by the same acute 
manipulations to HCRTr1 activity which influence motivated behavior [69, 80]. Armed 
with this knowledge, we applied our method of viral knockdown to measure the 
neurochemical correlates of the behavioral experiments. At the same respective time 
points, we observed substantial reductions to multiple measures of baseline signaling. 
Electrically stimulated DA release was diminished by around 70% per pulse, while 
baseline DA uptake, a measure which is normally unaffected by acute SB treatment, 
also decreased by a sizable margin. These effects on baseline suggest that HCRTr1 
expression is important for the maintenance of activity at the soma and dendrites of 
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dopaminergic cells (the site of the electrical stimulation). We then utilized cell-specific 
knockdown of HCRTr1, and began stimulating the DA terminals, in order to further 
discern the presynaptic effects at the DA terminal. Upon stimulation of the terminal, 
we found that HCRTr1 knockdown did not affect baseline DA release. This discrepancy 
was not in itself all that surprising. HCRTr1 are located primarily on the soma and 
dendrites of dopaminergic cells, where they regulate the excitability through various 
signaling pathways. For this reason, a change in HCRTr1 density would be expected to 
reduce the excitability of the cell body of DA cells, and therefore lower the response 
to an electrical stimulation in this area. By comparison, HCRTr1 are not located at the 
DA terminals in significant numbers, and therefore the effects on the localized 
excitability of this region (which is stimulated in the ex-vivo experiments), may be 
much less readily apparent, and only detectable at the highest levels of 
pharmacological manipulation. Indeed, we did observe a significantly reduced effect 
of high-dose cocaine on DA uptake inhibition, a finding which suggests that HCRTr1 
may be affecting DAT activity. Indeed, the decrease in baseline DA uptake (as well as 
the blunted effect of cocaine at the DAT) may represent a potential compensatory 
effect of reduced DA production. With less DA in the synapse, cells may reduce the 
surface expression or functionality of the DAT, in order to attempt to preserve 
synaptic DA levels. While such an effect would not create more DA, it would allow DA 
to remain in the synapse longer and provide greater stimulation of DA receptors. 
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These effects would explain the lower baseline rate of DA uptake, the lower 
proportional presynaptic response to cocaine, and potentially the greater postsynaptic 
response to cocaine, observed in KD animals. 
 
While qRT-PCR revealed that the level of DAT was largely unaffected, it is possible 
that viral downregulation of HCRTr1 produces nuanced changes which can alter the 
activity (if not the expression) of the dopamine transporter. The literature supports 
several possible signaling mechanisms linking HCRTr1 to DAT activity, including 
changes in phosphorylation via PKC and ERK1/2- regulated pathways, [288]. While we 
did not evaluate these pathways in detail, it is clear that HCRTr1 may be a key 
regulator of DAT expression, and in the larger sense, on the nature of the presynaptic 
DA environment.  
 
As HCRTr1 appears to regulate at least some of the presynaptic DA dynamics, it is 
also likely to be influential on the activity of post-synaptic regions which are heavily 
dependent on DA input. Our in-vivo investigations into the firing rate of MSNs 
suggest that the effects of HCRTr1 in the VTA may have strong ramifications for many 
regions, including the NAc. While the baseline firing rates were only slightly different 
between control and knockdown groups (and both were within the well-established 
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range of firing) [257], we did observe an increase in the relative number of Type 1 
(dopamine excited) MSNs, as well as an increased cocaine response in Type 1 MSNs. 
The increased sensitivity of Type 1 cells is consistent with an increase in D1 receptor 
activity [289, 290]. The relative lack of change at D2 is not entirely unexpected; D2 is 
considered to be somewhat more resistant to short term changes in DA levels [274]. 
Given that the slice preparation involved cocaine concentrations that persisted over 
the order of minutes, it is possible the timeline was not sufficient to produce 
substantial changes in the surface expression of D2. Together, the results indicate that 
HCRTr1 expression in the VTA is important for presynaptic DA function, and may have 
additional ramifications for postsynaptic environments as well.  
 
 Such findings lend further weight to the hypothesis that HCRTr1 is critical for 
maintaining DA neurotransmission, as even small changes to HCRTr1 expression can 
produce significant alterations to DA release, motivated behavior, and even the 
activity of efferent regions. While the expression of DAT, TH, and D2R mRNA levels at 
the soma were largely unchanged, changes in DA protein levels are not even 
necessary for dopamine dysfunction. Even Parkinson’s disease, which is categorized 
by a reduction of TH activity, is not defined by a loss of TH (aside from that resulting 
from the death of DA neurons), but rather to a change in binding to α-Synuclein, a 
co-factor of TH [291]. These types of effects are consistent with the literature, as 
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HCRTr1 blockade can reduce excitability [26], and reduce dopamine [67], without 
necessarily altering the expression of fos immunoreactivity in dopaminergic neurons 
[62]. For this reason, it is plausible that HCRTr1 KD could be inducing very significant 
effects on cell physiology, even without reducing the mRNA expression in the soma or 
protein expression at the terminal (as observed in our studies).  
 
 
Viral knockdown as an experimental tool 
 
The findings detailed in this document would not have been possible without the 
advantages brought on by viral-mediated shRNA knockdown. Viral knockdown 
enables the selective targeting of genes of interest (in this case HCRTr1) in a region-
specific manner, with the minimum of adverse side effects. This is due largely to its 
mechanism of action. The shRNAs code for antisense sequences, and therefore do 
not lead to actual proteins being created. Furthermore, the shRNA can only interfere 
with translation when it is bound to the targeted mRNA in the cytoplasm, and 
therefore there is a quantity of targeted mRNA (in this case ~65%) which can evade 
the viral antisense sequence, and maintain a level of functionality to the system, 
allowing future experiments to probe at the limits to the system. While intra-cranial 
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infusions of viral vectors are unlikely to be the final method of delivery for future 
treatments of addiction, our shRNA interventions have proven to be useful tools for 
evaluating the role of a specific neuropeptide system throughout the progression of a 
chronic disease state. Addiction is a debilitating disease process that induces many 
long-term changes to the CNS. Hence, a treatment that may be effective early on in 
the process may not produce desired effects at a later time point, once patterns of 
dopamine signaling have changed and receptor expression has shifted. Hence, it is 
critical to induce a long-term method which can adapt to the changes which are 
occurring in the cellular environment. Our viral method was effective in this regard, by 
producing shRNA interference of a sizable percentage of the HCRTr1 mRNA’s being 
produced. As such, its function is largely scaled to the current degree of HCRT 
expression, and as such, will produce largely even effects throughout the experiment, 
compared with, a standardized dose of antagonist, which may have a different level of 
effect if HCRTr1 expression is changing. Finally, viral knockdown does not require 
behaviorally stressful injections or the implantation of a pump.  
 
As hypocretin manipulations have been shown to alter motivated behavior in different 
ways, depending on the degree of alteration to receptor activity, as well as on the 
nature of the behavior, it is critical to better clarify the dopaminergic mechanisms 
which link HCRT to behavior.  In addition, it was also important to quantify the extent 
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to which the mechanism was driven through dopaminergic cells, which comprise only 




This research has led to many important observations about the ongoing role of 
HCRTr1 in the VTA. In future experiments, the effects can be better parsed out, with 
the variety of tools at our disposal. First, it would important to evaluate effects on 
dopamine in a freely-moving preparation. Dopamine levels are profoundly depressed 
before and following cocaine, and both acquisition and motivation appear to be 
effected. For this reason, it will be important to understand how HCRTr1 manipulation 
changes DA signaling (cue- and reinforce-driven) over time. We can also utilize whole 
cell-patch clamp electrophysiology to directly measure changes to the excitability of 
dopaminergic cells. This is one key experiment we were unable to perform in the 
current research, and determining the effects on DA cell excitability would likely 
provide a great level of clarity with which to interpret the current findings.  
 
Finally, we can further evaluate the cell-specific contributions to behavioral effects. 
Further investigation into the molecular impact on D1- and D2- driven pathways 
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could reveal significant information about the precise mechanisms by which HCRTr1 
alters DA signaling (as it does not appear to occur through direct alterations to the 
expression of DA protein levels).  
 
Finally, implications to the post synaptic environments will be better modeled in future 
studies. We have demonstrated that TH-specific knockdown of HCRTr1 may have 
important effects on the firing rate of medium spiny neurons in the NAc. However, it is 
unclear whether other cells are also affected, and whether the degree of effect is 
stronger on D1 or D2 MSNs. Future experiments may utilized D1 and D2 specific 
antagonists to determine the effects of knockdown, as opposed to DAT blockers such 




Together, we have significantly expanded upon the body of hypocretin research, and 
furthered the utility of an important experimental tool for studying neuropeptide 
systems. We determine a long-term methodology which may provide a context 
through which further acute investigations of the HCRT system may occur. While 
further research will be necessary in order to fully understand the ongoing role which 
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HCRTr1 performs in the VTA, it is clear that we have identified a key neurochemical 











Figure 13. Predicted model of effects of HCRTr1-KD. HCRTr1 KD reduces HCRT-
dependent activation of phospholipase C, which leads to less cleavage of PiP2, 
producing less DAG and IP3. This leads to reduced release of intracellular calcium 
(and calcium-dependent activity) as well as reduced activation of PKC. These two 
effects affect dendritic glutamate receptors and calcium-dependent kinases, leading 
to reduced excitability of dopaminergic cells, which depresses the firing rate. This loss 
of excitation, coupled with the loss of PKC activation, downregulates the activity of 
DA-dependent enzymes such as TH and VMAT, thereby reducing DA release. The loss 
of PKC activity, combined with the reduced DA release, likely causes a change in the 
membrane availability of DAT at the terminal, slowing baseline DA uptake and 
reducing the sensitivity to psychostimulants such as cocaine. The loss of DA and 
slower rate of DA recycling likely leads to a corresponding postsynaptic upregulation 
of dopamine receptors (with excitatory D1 receptors appearing to exhibit this change 
first). Such postsynaptic effects lead to alterations in the excitability of medium spiny 
neurons in the NAc, ultimately changing the level of input to the ventral pallidum and 








For the behavioral experiments of chapter 4, we also performed investigations into the 
effects of HCRTr1 KD on the acquisition and motivation for cocaine self-administration 
at 2 weeks post-transfection. We observed a strong trend towards significance in the 
number of days to acquire criteria (HCRTr1 KD = 4.66 +/- 1.06) (SCRM = 2.85 +/- 
0.85) (t(9)  = 1.89, p = 0.06) (A). Upon switching to the higher-effort PR schedule, we 
determined no major significance in the average breakpoint over the course of the 
experiment (HCRTr1 KD = 13.35 +/- 2.62) (SCRM = 16.27 +/- 1.90) (t(9)  = 0.77, p > 
0.1).  Two-way repeated measures ANOVA indicated no significant effect of viral 
treatment (F(1,9) = 1.52, p > 0.1) nor a significant effect of time (F(9,79) = 2.11, p > 0.1) 


















Supplemental Figure 1. (A) Shown are mean ± standard error of the mean (SEM) for 
days to acquire cocaine self-administration in SCRM and KD animals under the FR1 
schedule. (B) Shown are the mean ± standard error of the mean (SEM) breakpoints 
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